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Abstract 
AIM: 
To study the demographic profile, clinical presentation, diagnostic features, 
angiographic findings and treatment outcomes of patients with Takayasu arteritis. 
SPECIFIC OBJECTIVES : 
      1.     To study the demographic profile of Indian patients with Takayasu arteritis. 
2.     To study the modes of clinical presentation of patients with Takayasu arteritis. 
3.      Evaluation of the applicability of different diagnostic criteria to Indian patients                   
  with Takayasu arteritis. 
4.    To study the angiographic findings in Takayasu arteritis based on aortography,    
       peripheral and coronary angiography and to asses response to medical therapy and     
       interventions in Takayasu  arteritis patients. 
METHODS:  
           Observational study done in Department of Cardiology, Christian Medical 
College  
 Vellore,  in  which  we  analyzed  demographic,  clinical,  epidemiological, 
angiographic and  
treatment data of 125 Takayasu arteritis patients. 
RESULTS:  
We studied a total 125 patients with Takayasu arteritis over a period of one and a half 
years.  Their demographic, clinical and angiographic profiles were analysed. The mean age of   
patients in this study was 32 ± 13 years.  The disease showed a predilection for females, with 
female-to-male ratio of 3.5:1.  Type V disease was most common in the present study.  A 
third of the patients had cardinal symptoms and half of the patients had  heart related 
symptoms, of which exertional dyspnoea was most common. 
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 About 40% of the patients had neurological symptoms, of which giddiness, blurred 
vision and syncope were common presentations.  Almost 60% of patients were hypertensive, 
and renal artery stenosis was angiographically seen in 48% of patients. Upper limb ischemia 
presented as right, left or bilateral upper limb claudication with an equal frequency of 25%, 
while bilateral lower limb claudication was more common (26%) as compared to isolated 
right or left lower limb claudication (6% each). 
95% of patients met the clinical criteria for diagnosis and 89% of patients had American 
college of rheumatology score (ACR) ≥ 3.  Indian Takayasu Activity Score (ITAS) of ≥3 was 
found in 95% of patients.  Angiography showed 60% involvement of arch vessels, 30% 
involvement of abdominal aorta and 36% involvement of its major branches. Coronary and 
pulmonary artery involvement was seen in 14% and 6% respectively.  Statistically significant 
(p= 0.029) higher carotid intima-medial thickness >0.9 mm was found in active disease state. 
Patients follow up showed good response to both medical and interventional therapy 
for the disease.  Almost half of the patients had active state of disease at the first visit and this 
decreased to 25% at the last follow-up visit.  A third of the patients showed good response 
and half of the patients showed satisfactory response to medical treatment.  About half of the 
patients had good response to interventional treatment and a third showed satisfactory 
response to interventional treatment in present study. 
. 
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INTRODUCTION: 
 Takayasu arteritis is an idiopathic inflammatory disease of the large elastic arteries, 
seen commonly in young patients and resulting in occlusive or ectatic changes, mainly in the 
aorta and its major branches1.  Pathogenesis of Takayasu arteritis has long been studied, but 
the cause still remains uncertain.  Patients often first notice disease symptoms in the second 
or third decades of life. Takayasu arteritis can present as pulseless upper extremities and so is 
commonly referred to as “pulseless disease”2,3. 
 The clinical presentation is varied and can be divided into early inflammatory (pre-
pulseless) and late (pulseless) phase4.  In the majority of patients this disease is insidious in 
onset. Ishikawa5 reported insidious onset of symptoms in 76 % and sudden onset in 24%. 
Diminished or absent peripheral pulses, limb claudication and blood pressure discrepancies6 
are common presentations.  Clinical presentation depends upon, the vessel involved by the 
stenotic or occlusive lesions, such as the aortic arch (pulseless disease), descending thoracic 
or  abdominal aorta (atypical coarctation)7, renal arteries (reno-vascular hypertension)8, 
coronaries and pulmonary arteries.  Non-specific features include fever, night sweats, 
malaise, weight loss, arthralgia, myalgia and mild anaemia.   
  The disease shows geographical variation; Japanese patients present with “reversed 
coarctation” 9,10.  In south East Asia and Africa, descending thoracic and abdominal aorta 
involvement with renovascular lesions, called “middle aortic syndrome” is seen more 
commonly11.   
  Takaysu arteritis is a granulomatous pan-arteritis12 involving all the three layers, 
causing extensive intimal proliferation and inflammation of the tunica media and adventitia 
followed by fibrous scarring.  More acute inflammation can destroy the arterial media and 
lead to aneurysm formation13. The disease is classified into 5 types on the basis of 
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angiographic findings14. These systems are useful in comparison of patients and for planning 
management. Aortic incompetence used to be the principal cause of mortality of Japanese 
patients15, while cerebrovascular accidents due to hypertension have been the main cause of 
death in other countries.  Various modes of treatment including immunosuppression, vascular 
surgery, balloon angioplasty and stenting have been used for the management of these 
patients. 
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AIM AND OBJECTIVES 
AIM: 
The Aim of the Study was to study the demographic features, clinical presentation, 
application of diagnostic criteria, angiographic profile and treatment outcomes in 
patients with Takayasu arteritis. 
Objectives: 
1. To study the demographic profile of Takayasu arteritis patients at our centre. 
2. To study the spectrum of clinical presentation of Takayasu arteritis patients. 
3. Evaluation of patients using different diagnostic criteria (clinical diagnostic criteria,   
            American college of rheumatology criteria and Indian Takayasu Arteritis activity         
            Score). 
4. To study angiographic findings in Takayasu arteritis patients based on aortogram,  
            peripheral, coronary and pulmonary angiogram. 
5. To study the disease activity based on inflammatory markers ESR and CRP. 
6. To assess the response to medical (immunosuppressive) therapy and interventions at   
            follow-up. 
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Review of Literature 
Takayasu arteritis is idiopathic, non specific granulomatous vasculitis involving large 
and medium size vessels especially aorta and it’s main branches as well as pulmonary artery 
and it’s branches16, has strong female predisposition (8:1)17 and causes various types of aorto-
arterial occlusion and dilatation. Historically, Takayasu arteritis was named after Mikito 
Takayasu a Japanese ophthalmologist who first called attention to peculiar wreath-like 
arteriovenous anastomoses around the papillae of the retina, in the year 1908 18.  Because of 
its predilection for arch vessels, leading to absent peripheral pulses, this has been called 
pulseless disease19 or aortic arch syndrome and descending thoracic or abdominal aorta 
involvement has been called atypical coarctation20.  In some instances Takayasu arteritis 
patients may develop aortic aneurysm and aortic valve incompetence with ascending aortic 
dilatation21.  The inflammatory process leads to stenosis and occlusion of the involved 
arteries or aortic aneurysm formation22,23.  The clinical presentation depends on the involved 
vessel that presents the stenotic or occlusive lesions which can lead to secondary 
hypertension, retinopathy, cardiac involvement, cerebrovascular events and premature death.  
The prognosis and course of patients with Takayas arteritis shows wide variation and 
mortality has been reported to be as high as 20% at 5 years24. The aetiology of Takayasu 
arteritis remains unknown and various modes of treatment including steroids, balloon 
angioplasty and recanalization of occluded vessels, peripheral stenting and vascular surgery 
have been used for management of these patients.  Cardiac, renal and cerebrovascular 
complications are the major contributors of morbidity and mortality.  
EPIDEMIOLOGY: 
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The typical age distribution of Takayasu arteritis at initial presentation ranges from 
childhood to the third decade of life25. In about 80% of cases, clinical manifestations of the 
illness appear during the second to third decade of life but early onset of disease in childhood 
and occasionally up to late middle age26 at onset (up to 66 years) also have been reported.  In 
a previous case series, Sharma et al27 have shown that childhood onset of disease is not 
uncommon, comprising about one third of all cases.  Takayasu arteritis patients often notice 
the symptoms of the disease between 15 and 25 years of age, often there is delay in diagnosis 
of months to years noted from the onset of first symptoms in Takayasu arteritis patients.  NIH 
studies by Kerr et al suggested that the delay in diagnosis was longer in children28and up to 
four times that of adult patients29. 
Takayasu arteritis is a rare disease showing ethnic differences in epidemiological 
distribution, reported all over the world and seen most commonly in Asia and Mexico.  
Takayasu arteritis has a predilection for females, with a female-to-male ratio of 8 – 9: 1; 
unequal sex distribution30 is less clear in children. 
Takayasu arteritis showed an approximate incidence of 2.6 cases per year per million 
head of population in North America31. This is a progressive disease and has poor prognosis. 
It is the most common cause of systemic hypertension in Asian children32. 
Clinical presentation and pattern of vascular involvement in Takayasu arteritis also 
shows geographical variation.  The vessels involved in Takayasu arteritis vary in different 
parts of the world:  aortic arch and arch vessel involvement (reversed coarctation)33,34, is seen 
more commonly in Japanese patients, whereas in Indian Takayasu arteritis patients abdominal 
aorta and its main branches (middle aortic syndrome)35 are more commonly involved.  In 
Japan aortic incompetence is main cause of mortality while cerebrovascular accident 
secondary to hypertension is the main cause of death in other countries.  Takayasu arteritis 
patients show premature atherosclerosis because of underlying chronic inflammation. 
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Genetic predisposition in Takayasu arteritis also shows geographical variation so far 
as HLA association is concerned. Dong et al36 and Kasuya37 et al described high association 
with HLADR2, MB1, BW52, DW12, DW1 in Japan.  In India HLAB5 and B21 are more 
prevalent in Takayasu arteritis patients. 
PATHOGENESIS 
 
Even a century after the first description of Takayasu arteritis the exact 
etiopathogenesis remains unknown, though various possible aetiologies have been postulated 
based upon clinical associations. Infection is often considered to play a triggering role in the 
pathogenesis of Takayasu arteritis.  Tuberculosis and viral infection have been investigated 
for a long time, but so far no definite association has been demonstrated, although Takayasu 
arteritis is more prevalent in those parts of world having higher incidence of Tuberculosis.  In 
an Indian series of Takayasu arteritis patients Sen. et al38 reported evidence of tuberculosis in 
71% of their patients. 
Study of lesions, in active phase showed that inflammation results from cell mediated 
immunity response.  Heat shock protein HSP – 65, plays a important antigenic role49 in  the 
pathogenesis of  Takayasu arteritis.  Acute lesions contain mononuclear cell infiltrates that 
appear to have entered the vessel wall through the vasa vesorum, which subsequently migrate 
to the arterial intima.  These cells are predominantly macrophages and T cells40. The presence 
of various cytokines including IL – 6 and TNF in these granulomatous lesions has prompted 
various therapeutic options using cytokines targeted biologic agents. 
Takayasu arteritis is a pan-arteritis involving all the three layers of the arterial wall 
and causes extensive intimal proliferation and inflammation of tunica media and adventitia 
associated with significant fibrous scarring. 
The aortic intima shows tree bark appearance in the advanced critical stage.  Skipped 
lesions are a characteristic finding which are produced by a combination of both active 
inflammatory lesions and old fibrous lesions. Eventually, this inflammation can cause 
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atherosclerosis.  Calcification and thickened intima are also characteristic. It is sometimes 
difficult to differentiate Takayasu arteritis from atherosclerosis.  With the rapid progression 
of these changes the artery or aorta becomes dilated and forms aneurysm. The 
histopathological pattern is divided into granulomatous type, diffuse proliferative type and 
fibrous type. 
 Histological changes in early stage consist of mononuclear infiltrate associated with 
perivascular cuffing of the vasavesorum followed latter by intense mononuclear inflammation 
of the media may occur, sometime accompanied by granulomatous changes , giant cells and 
patchy necrosis of the media.  Panarteritic inflammatory infiltrate causes marked thickening 
of the affected arteries and subsequent luminal narrowing and occlusion. 
Takayasu arteritis has been shown to affect the parenchyma of various organs .Dilated 
cardiomyopathy; myocarditis and pericarditis have also been reported.  Heart failure may be 
due to valvular incompetence or hypertension.  Isolated cardiomyopathy may be the possible 
mechanism of heart failure in 5% of cases41.  Aortic incompetence seen in 7.24% 42Mitral 
regurgitation is seen in 11.4% 43 cases of Takayasu arteritis.  The disease is subdivided into 
the early or active phase and the late, chronic or inactive phase. Aortic regurgitation also 
develops and is consider as contributory factors for mortality. Aortic regurgitation develops 
because of annular or ascending aorta dilation or fibrous thickening, rolling, retraction and 
calcification of aortic valve.  Hypertension develops because of reduced elasticity of arterial 
wall (wind-kettle), atypical coarctation (proximal hypertension) and renal artery stenosis 
(renovascular hypertension)44 .  
CLINICAL FEATURES : 
  
 Takayasu arteritis clinical manifestation varies from asymptomatic disease found in 
the form of impalpable pulses or bruit to neurological manifestation in the form of cerebro 
vascular accident or seizure.  Clinical presentation of Takayasu arteritis is basically depends 
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upon phases of disease, which is divided into two phases, first pre-pulseless phase and second 
occlusive phase45,46.  
 The phasic clinical presentation of Takayasu arteritis is as follows: 
1. Pre-pulseless phase (Systemic Stage) : 
 Characterised by -   
 Symptoms due to inflammation of the artery before  any occlusion. 
 40-50% of total patients present at this stage. 
 Constitutional Symptoms47 include –  
• Fatigue 
• Fever 
• Weight loss 
• Non-pleuritic pain 
• Myalgia 
• Artharlgia. 
 
2. Occlusive Stage: 
 50-60% of patients contribute this stage. 
Occlusive stage in vessels produces ischemic phenomenon48 which are 
responsible for symptoms depends upon the site. 
 
Vascular49. 
1. Hypertension – Most common presentation in  children 
                                            Due to  involvement of renal artery. 
2. Syncope – due to involvement of Arch vessels. 
3. Back pain – due to involvement of aorta. 
4. Claudication of jaw and extremities. 
 
Neurological Symptoms 50  
 Dizziness / Giddiness 
 Syncope 
 Transient ischemic attack 
 Stroke 
 Amaurosis 
 Blurred Vision 
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 Neck Pain / Carotidynia 
 Seizure 
  
Heart Related Symptoms51 
 Exertional Dyspnoea 
 Paroxysmal nocturnal dyspnoea / Orthopnea / Pedal Oedema 
 Angina 
 Palpitation 
 
Renal / Aortic : 
 Hypertension 
 Renal Failure 
Upper limbs symptoms: 
            In the form of right and left upper limb fatigue and claudication and bilateral upper 
limb fatigue and  claudication. 
Lower Limbs symptoms: 
             In the form of right and left lower limb fatigue and claudication and  bilateral 
lower limb fatigue and claudication 
Miscellaneous: 
 Head ache 
 Abortion 
 Gastro intestinal Bleeding 
Tuberculosis 
 Epitasis 
Signs in Takayasu arteritis: 
• Systolic blood pressure differences more 10 mmHg. In both arm 
• Absent or diminished peripheral pulses 
• Arterial bruit 
• Carotid shudder 
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• Ophthalmological changes 
• Pallor 
• Muscle wasting. 
Characteristic clinical features of Takayasu arteritis: 
 
• Discrepancies in peripheral pulses and blood pressure - 84 to 96%52. 
•  Hypertension - 33-83% of patients53 (it reflects renal artery stenosis which is seen in 
28-75% of patients)54. 
• Vascular bruits - 80-94% of patients55                                                                                                                                                        
• Eye involvement - 37% of patients56. 
• Aortic regurgitation - due to dilation of the ascending aorta, separation of the valve 
leaflets, and valve thickening. 
• Hypertension, aortic regurgitation and dilated cardiomyopathy lead to Congestive 
heart failure. 
• Hypertension and ischemia leads to neurological manifestations. 
•  Pulmonary artery involvement - 14-100% of Takayasu arteritis patients, finding of 
Oligaemic lung fields correlate with pulmonary vasculopathy in approximately 30% 
of patients57. 
• Other symptoms include dyspnoea, headaches, carotidynia, myocardial ischemia, 
chest wall pain and erythema nodosum. 
                  In cases of Takayasu arteritis progression of inflammation causes gradual 
narrowing of vessel and which leads to development of characteristic symptoms and 
influenced by development of collateral circulations. The occlusive fibrotic phase is 
dominated by ischemic symptoms including angina, claudication, syncope and visual 
impairment, hypertension from renal artery stenosis, aortic regurgitation from aortitis or 
stroke from carotid artery occlusion. 
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                  The disease commonly presents in the second or third decades of life, often with a 
delay in diagnosis from the onset of first symptoms of few months to years.  Kerr58 suggested 
that the delay in diagnosis was longer in juveniles, being up to four times that of adult 
patients.  However data from India looking at patients aged less than 18 years demonstrated a 
delay of only 2.5 to 5.5 months.  This discrepancy presumably relates to the difference in 
disease incidence between the two populations, which results in differences in awareness.  
The clinical features and progress of young patients with Takayasu arteritis appear to be very 
similar to those of adults59. 
             Hypertension in Takayasu arteritis is due to either aortic or renal artery stenosis and 
may be secondarily leading to hypertensive encephalopathy, cerebrovascular accident and 
heart failure60. Hypertension is a frequent finding and seen in more than 50% of adult 
patients61,62,63. 
              Aortic root dilatation and loss of coaption of the aortic valve leaflets leads to aortic 
incompetence.  The severity of aortic incompetence is so that the patient can progress to 
congestive heart failure because of left ventricular dilatations and left ventricular systolic 
dysfunction.  Direct myocardial involvement, coronary artery disease and hypertension may 
also lead to congestive heart failure64. 
Transient ischemic attacks, cerebral infarction, headache, hypertensive 
encephalopathy and seizures are the main neurological manifestations65 of Takayasu arteritis. 
15-20% of patients showed typical ocular finding in Takayasu arteritis patients. 
 
 
 
Diagnosis: 
 
Diagnosis of Takayasu arteritis is based upon clinical criteria proposed by Ishikawa 
in 1988.  Ishikawa suggested a set of criterion to differentiate atherosclerosis from the 
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Takayasu arteritis, with a sensitivity of 84 percent in his series of 96 patients of Takayasu 
arteritis.  
 The Ishikawa criteria comprises of one obligatory criteria, two major criteria and 9 
minor criteria. 
            Obligatory  criteria  - Age < 40 years. 
 Major criteria   - Left mid subelavian artery lesion  
      Right   mid subelavian artery lesion 
 Minor criteria              - Elevated ESR, Carotid artery tenderness, hypertension, aortic    
incompetence, annulo aortic ectasia, pulmonary artery lesion, left mid common carotid 
lesion, distal brachiocephalic lesion, descending thoracic aorta lesion, abdominal aorta lesion.  
 But there are number of pitfalls of this criteria  
1. Geographic and racial variations of this disease not considered. 
2. Obligatory criteria of age < 40 years - A significant number of patients with Takayasu 
arteritis had age of onset more than 40 years. 
3. Emphasise active signs and symptoms of 1 month duration before the age of 40 years. 
4. No clear criteria for abdominal aortic lesion and absence of lesion in aorto iliac 
region. 
Modified Diagnostic Criterion for Takayasu arteritis66 
Major Criteria 
1. Left midsubclavian artery lesion : stenosis or occlusion 1 cm proximal to the left 
vertebral artery orifice up to 3 cm distal 
2. Right midsubclavian artery lesion : stenosis or occlusion from the right vertebral 
artery orifice to 3 cm beyond 
3. Characteristic signs and symptoms (> 1 month duration)  
A. Limb claudication 
B. Pulselessness or blood pressure difference  > 10 mm Hg in arms 
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C. Exercise ischemia 
D. Neck pain 
E. Fever 
F. Amaurosis fugax 
G. Syncope 
H. Dyspnoea 
I. Palpitations 
J. Blurred vision 
Minor criteria 
1.   High ESR: Westergren ESR > 20mm at one hour. 
2.   Carotidynia 
3.    Hypertension : brachial blood pressure > 140/90 mmHg popliteal blood pressure >     
  160/90mmHg 
4.   Aortic regurgitation or annuloaotic ectasia : determined by auscultation,     
        arteriography or echocardiography. 
5.     Pulmonary artery lesion : lobar or segmental artery occlusion, or stenosis or    
          aneurysm of pulmonary trunk. 
6.     Left middle common carotid artery lesion: stenosis or occlusion of middle 5 cm    
           portion starting 2 cm from its orifice. 
7.      Distal innominate artery lesion: Stenosis or occlusion in the distal third. 
8.      Descending thoracic aorta lesion: narrowing, aneurysm, or luminal irregularity. 
9.      Abdominal aortic lesion: narrowing, aneurysm, or luminal irregularity. 
10.     Coronary artery lesion: documented by arteriography in patients < 30 years of age    
          and without risk factors for atherosclerosis. 
       Clinical Diagnosis of Takayasu arteritis is made by above criteria  
  If - 2 major  
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           Or 
  1 major + 2 minor 
        Or 
  4 minor criteria met. 
Sharma et al modified Ishikawa criteria for the diagnosis of Takayasu artertis. The 
modification include  
1. Removal of obligatory criteria of age < 40 years67 
2. Inclusion of characteristics signs and symptoms as major criteria. 
3. Removal of age in defining abdominal aortic lesion 
4. Addition of coronary artery lesion in absence of risk factors  
This modified criteria as a sensitivity of 92.5% and specificity of 95% in angiographically 
proven Indian Takayasu artertis patients and higher than that of Ishikawa criteria. This 
criteria should sensitivity of 96% and specificity 96% of in a series of japans Takayasu 
arteritis patients68. 
Ishikawa criteria for diagnosis of Takayasu arteritis showed sensitivity of 92 percent 
and specificity of 95 percent. 
Active Takayasu arteritis disease patients found to have higher sensitivity for 
Ishikawa criteria. 
Another criteria for diagnosis of Takayasu arteritis was given by American College of 
Rheumatology in 199069. 
I. Extremity claudication 
II. Decreased BA pulsation 
III. 10 mmHg differences in Systolic Blood  Pressure of both arms 
IV. Arteriographic narrowing 
V. Subclavian artery  or abdominal aortic bruit 
VI. Age at onset of less than 40 years 
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Presence of at least three or more of these criteria make the diagnosis of Takayasu 
arteritis.  ACR criteria for the diagnosis of Takayasu arteritis have sensitivity of 91 percent & 
specificity of 98 percent. 
 Clinical features which help to reach the diagnoses are hypertension, vascular bruit, 
absent or diminished peripheral pulses, asymmetrical arm blood pressures and other ischemic 
symptoms.  Prominent symptoms of the disease are non specific or it may be absent in 70 % 
of patients in the early stage of the disease. 
Angiography is the gold standard tool for the diagnosis and classification of Takayasu 
arteritis70,71.. Non-invasive diagnostic modalities like computed tomography, magnetic 
resonance angiography allows an early and easy diagnosis of Takayasu arteritis. Magnetic 
resonance angiography is preferred in paediatric patients because it avoids use of radiation 
and nephrotoxic contrast.  Measurement of arterial wall thickness and acute phase oedema 
can be measured by magnetic resonance imaging.  
18F–fluorodeoxyglucose (FDG) PET computerised tomographic imaging are now used 
as updated diagnostic tool for early diagnosis of Takayasu arteritis. PET detects labelled 
glucose uptake, which is an indicator of metabolic activity and up regulated in inflammatory 
conditions72 but noticed in other states like cell activations and healing. It allows the 
visualization of distributions of lesions and area of inflammatory activities in aorta. In 
response to therapy when inflammation disappears PET showed weak FDG accumulation. 
Takayasu arteritis activity usually monitors by non invasive markers like ESR and 
CRP but these are non specific inflammatory markers and have low sensitivity and 
specificity. Matrix metalloproteinase 2 can be use for the diagnoses of Takayasu arteritis and 
3 and 9 serve as activity markers. 
Differential diagnoses includes inflammatory aortitis, syphilis, tuberculosis, 
rheumatoid arthritis, lupus, Behcet’s disease, Kawasaki disease and giant cell arteritis, 
developmental abnormalities and other aortic pathology  but specific features of most of the 
24 
 
above conditions enable the diagnosis. Fibro muscular dysplasia causing hypertension is an 
important differential diagnosis. 
Classification of Takayasu arteritis 
Lupi-Herrera et all in 1977 revised the early system of classification in Takayasu 
arteritis, which was superseded by the new classification of Takayasu arteritis in 1994, by the 
XIth international conference on Takayasu arteritis based on angiographic findings. 
Takayasu arteritis Conference – 1994 – angiographic 
classification73 
 
Type             Vessel involvement 
Type I          Branches from the aortic arch 
Type IIa       Ascending aorta, aortic arch and its branches 
Type IIb      Ascending aorta, aortic arch and its branches, thoracic descending aorta. 
Type III      Thoracic descending aorta, abdominal aorta, and / or renal arteries. 
Type IV      Abdominal aorta and/or renal arteries 
Type V       Combined features of types IIb and  IV 
 
C + - involvement of coronary artery.        P + - involvement of pulmonary artery. 
Clinical classification of Takayasu arteritis (Ishikawa) 74 
Group                Clinical features 
Group I              Uncomplicated disease, with or without pulmonary artery involvement. 
Group IIA         Mild/moderate single complication together with uncomplicated disease. 
Group IIB         Severe single complication together with uncomplicated disease. 
Group III          Two or more complications together with uncomplicated disease. 
 
These classifications are useful in planning management and assessment of prognosis.  
Clinical classification described by Ishikawa was based upon the natural history and 
complications of the disease75. 
25 
 
CLINICAL SPECTRUM OF TAKAYASU ARTERITIS: 
 Moriwaki et al76 in their study on Takayasu arteritis described Indian and Japanese 
patients, in which Japanese patients were predominantly female and clinically presented with 
neurological manifestations like dizziness, vertigo, absent or diminished peripheral pulses 
and long duration of active phase of disease  and reflects  involvement of the aortic arch and 
its main branches while in Indian patients male are relatively more affected with headache, 
hypertension, and left ventricular hypertrophy suggesting a high frequency of lesions in the 
abdominal aorta and stenosis of the renal arteries, leading to Reno vascular hypertension. 
Takayasu arteritis patients may present with cerebrovascular lesions manifesting as 
ischemic symptoms which are common even in young patients because of the involvement of 
arch vessels77. About 10 – 20% of patients with Takayasu arteritis have Transient ischemic 
attacks or ischemic stroke78. Stroke occurs from a reduction in cerebral blood flow due to 
total occlusion of at least 1 or more arch vessels rather than from emboli.  Aortocervical 
bypass originating in the ascending aorta (and not from the subclavian artery) with distal 
anastomosis to the carotid bulb with the use of saphenous vein grafts is recommended79. 
Atypical Coarctation 
 
 
Takayasu arteritis is one of the causes of a much less common variety of aortic 
coarctation, the middle aortic syndrome, apart from the more common congenital coarctation 
of the aorta.  This atypical coarcation occurs anywhere along the length of the aorta except 
the ascending aorta, whereas coarctation of the aorta is typically located around the aortic 
isthmus. Satisfactory long-term results and survival seen after surgical management in a 
series of 33 patients from 1960 to 200480 .  
Renal Artery Stenosis (Renovascular Hypertension) 
Hypertension is a common occurrence in TA and is related to major complications 
such as congestive heart failure, cardiomyopathy, hemorrhagic stroke, hypertensive 
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encephalopathy and myocardial infarction81,82. Renal artery stenosis seen in 28-75% of 
Takayasu arteritis patients83,84. Renal artery stenosis as well as atypical coarctation or reduced 
elasticity of the arterial wall can cause hypertension. The less invasive percutaneous 
transluminal angioplasty is today the first choice of therapy. 
 
Coronary Artery Disease: 
 Coronary involvement was reported to be approximately 10% 85 in Takayasu arteritis. 
Coronary artery involvement can be in the form of proximal and ostial coronary artery 
disease or triple vessel disease. Patient with Takayasu arteritis having significant coronary 
artery disease can present as effort angina, rarely acute myocardial infarction, congestive 
cardiac failure or sudden cardiac death. In another study the coronary ostium was involved in 
87.5% of cases, and was treated surgically in 95.8%86 of cases with good outcomes for both 
stenotic and occlusive lesions. In yet another study obstructive coronary artery disease was 
found in 41.3% (n=19)87.  Successful angioplasty, especially with a drug-eluting stent, has 
been reported in proximal coronary disease in patients with TA88,89.   
Aortic Aneurysm: 
Takayasu arteritis commonly affects aorta and it’s major branches. The disease involves 
vessel wall and resulting in luminal irregularity, stenosis and aneurysm formation. In 
Takayasu arteritis aortic aneurysm is not a rare finding. An aorta having less calcification has 
more likelihood of developing aortic aneurysm. 
Takayasu arteritis patients usually have relatively good long term prognosis. However 
if aortic aneurysm forms,  it can lead to poor outcomes like heart failure due to aortic 
incompetence and rupture of aneurysm and which may be fatal. 
 Aneurysm formation is considered one of the major complications determining 
prognosis in TA90.  In Japan, the incidence of aneurysmal formation was reported to be 
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higher, between 22.2% and 31.9%91 although the incidence of aneurysm ruptures seems to be 
low92. Aneurysms can be treated both by open surgery and by endovascular repair93,94,95. 
Aortic Regurgitaion: 
 Aortic regurgitation, which is another major complication influencing prognosis, is 
also prevalent in Japan96,97.  It is commonly associated with ascending aorta or root dilation, 
which requires concomitant root and aortic valve replacement.  Composite graft root 
replacement has been considered a gold standard procedure98. However, prosthetic graft 
detachment (anastomotic false aneurysm) including a coronary disorder is the most serious 
morbidity in the long term, particularly in patients with persisting inflammation.  A novel 
“miniskirt technique”, in which the prosthetic valve is not attached directly to the fragile 
annulus, is used for composite graft root replacement to treat aortic regurgitation with root 
dilatation. 
Congestive heart failure: 
Hypertension, valvular incompetence and cardiomyopathy cause heart failure in 
Takayasu arteritis patients99.  Aortic incompetence contributes 7 percent and mitral in- 
competence 11 percent cases of heart failure in Takayasu arteritis. Less commonly heart 
failure may be due to myocardial dysfunction secondary to coronary artery disease.  About 44  
to 100 percent of Takayasu arteritis patients showed pulmonary artery involvement as shown 
in a studied done in Japan and Mexico but this percent is much less in Indian Patients.  Indian 
studies in Takayasu arteritis patients showed 26 to 36 percent involvement of pulmonary 
artery.  Takayasu arteritis patients showed pulmonary hypertension probable mechanisms are 
direct pulmonary artery involvement or left ventricular systolic dysfunction. 
 
Retinopathy: 
 Uyama and Asayama100 described 4 categories of typical retinopathy in Takayasu 
arteritis patient.  This is because of hypoxic changes due to decrease ocular blood flow. 
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Stage  - 1.  Dilatation of small vessels   
Stage - 2  Systolic retinal arterial pressure - 40 mmHg - Micro aneurysm formation. 
Stage – 3  Arteriovenous anastomoses 
Stage – 4  Proliferative  retinopathy  
Vitreous haemorrhage  
Retinal ischemia & rubeosis 
Cataract 
Neovascularisation 
 Mild and moderate forms - stages 1 and 2. 
Severe form                      - stages 3 and 4. 
A cross sectional study101 of Takayasu arteritis patients done at our centre showed 
both disease and treatment related eye manifestation. About one third of patients showed 
impairment of vision, typical takayasu retinopathy was seen in 16% patients, hypertensive 
retinopathy was noticed in 15% of cases, while ocular ischemic syndrome was found in 7% 
cases.  About one fourth patients was found to have cataract as a complication of treatment  
(steroid induced cataract).  Other rare ocular features noticed are iris neovascularisation, 
anterior ischemic optic neuropathy, steroid induced glaucoma and uveitis. A statistically 
significant finding of Takayasu retinopathy and ocular ischemic syndrome was noticed in 
patients who are having low blood pressure in both upper limbs. 
Takayasu arteritis patients are found to have hypoperfusive ocular manifestation in a 
form of ocular ischemic syndrome and anterior optic ischemic neuropathy102 shown in a 
study at the same centre. Secondary uncontrolled hypertension in these patients causes 
hypertensive retinopathy and some patient noticed advanced changes in the form of,  
exudative retinal detachment and papilledema.  
 
Natural History of Disease: 
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Natural  course of Takayasu arteritis extends for a long duration (may be many years), 
with varying level of disease activity at different point of time. Usually a triphasic pattern103 
of Takayasu arteritis disease expression is noticed which consist of non-vascular (systemic) 
phase, vascular inflammatory phase and burnt out phase. Only a small number of patients 
showed this classic pattern of disease, reason being that both inflammatory and fibrotic 
changes may coexist at the same time causing the chronic and recurrent nature of the disease. 
Takayasu arteritis patients often showed two distinct phases, pre-pulseless (active 
phase) and pulseless (chronic) phase.  Changes of phase usually take three months time but 
may be insidious.  The chronic phase of disease sometimes has acute exacerbations. Some 
patient may present directly in the chronic phase without active phase. Inflammation usually 
causes following presentations in the chronic phase –  
Stenosis or Occlusion  - 85 % 
Aneurysm                    - 02 % 
Combined                    - 13 % 
One-fifth of all patients with Takayasu arteritis present with monophasic and self-
limited disease. More aggressive course of disease is noticed in children with Takayasu 
arteritis disease. 
  Five years survival in Takayasu arteritis patients after diagnosis is 80% followed by 
flattening of survival curve with no further mortality. One series104 has shown a mortality rate 
as high as 35-40% by five years. Heart failure was found as most common cause of death in 
Takayasu arteritis patients. Young patients sometimes show spontaneous improvement in 
clinical manifestations of diseases. Long-term outcome is usually not changed by medical 
management of disease. Takayasu arteritis children usually reflect ominous prognosis if they 
have dilated cardiomyopathy. 
            Previous studies showed that early angioplasty improves survival benefits in 
Takayasu arteritis patients. Takayasu arteritis disease showed significant morbidity and 
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premature death. Predictors of premature death in cases of Takayasu arteritis are severe single 
complication or multiple complications, hypertension cardiovascular involvement and 
presence of severe functional disability. 
Prognosis: 
Takayasu arterits patients have relatively good long-term prognosis. Hypertension is 
important factor in patient of Takayasu arteritis as it causes heart failure, cerebraovascular 
accidents and renal failure, and makes survival worse by one-sixth. Hypertension or aortic 
incompetence leading to cardiac failure is the main cause of death in Takayasu arteritis 
patients. Studies of Takayasu arteritis patients in India showed five years cumulative survival 
after disease onset was 91% and 84% at ten years, while event-free survival rate was 75% 
and 64% at five and ten years105. 
Forty percent of deaths in the Indian cohort were the result of congestive cardiac 
failure.  Presence of a severe hypertension, cardiac involvement, and severe functional 
disability are useful in predicting premature death, premature event, or both on follow-up.  
Patients with none of above factors have a good long-term prognosis. 
20% of patients of Takayasu arteritis have self limiting and monophasic pattern of 
disease. A picture emerged as long term disability and reliance on steroids to reduce the 
remission rate 106. In one longitudinal study of 16 patients , 81% had one or more relapse but 
94% achieved long term remission107.One study suggested that a low ESR, early treatment 
with steroid and a stable condition at presentation were factors predicted a good prognosis108. 
Disease Activity in Takayasu arteritis 
 Assessment of disease activity in Takayasu arteritis is difficult.  Progression of 
disease in different phases of Takayasu arteritis, clinical features and vascular inflammation 
do not always correlate. 
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 A discrepancy was noted in about 40 percents of patients in clinical features and 
histopathology of samples collected at the time of surgery109. 
 Criteria  for active disease in patients with Takayasu’s arteritis110. 
1. Systemic features (fever, musculoskeletal symptoms, etc) 
2. Elevated erythrocyte sedimentation rate. 
3. Features of vascular ischemia or inflammation (claudication, vascular pain 
manifesting as carotidynia, diminished or absent pulse, vascular bruit), 
asymmetric blood pressure in either upper or lower limbs or both 
4. Typical angiographic features. 
 No accurate laboratory test is available to assess disease activity in Takayasu arteritis 
patients. Constitutional symptoms are present in 7-36% of patients with active disease111; 
this, when associated with high levels of acute phase reactants is suggestive of active disease 
state in Takayasu arteritis. Histopathologic examination of samples from involved arteries is 
considered the gold standard for the diagnosis of active inflammation in Takayasu arteritis, 
but this is usually not feasible unless the patient is going for surgery. 
 Constitutional symptoms like easy fatigability, arthralgia, limb claudication and 
hypertension are usually present in 50 percent of patients at the onset of the disease112.  After 
establishing the diagnosis of Takayasu arteritis it is mandatory to decide disease activity to 
start treatment with immunosuppressive drugs. 
 [[  
1.Parameters used to asses the Disease Activity: 
1.1 Acute phase reactants (ESR and CRP)  
Takayasu arteritis patients with active disease have an elevated ESR of more than 20 
mm in one hour.  But ESR was not found to be reliable marker for diagnosis for Takayasu 
arteritis, as about one third of active Takayasu arteritis patients have a normal ESR and about 
40 percent of burned out stage of disease showed an elevated ESR113. 
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Persistently elevated ESR is consider as a marker of disease activity, inflammation 
disease progression. Ishikawa noted in his case series that about half of the patients have 
elevated ESR.  Higher value of ESR is noticed in younger patients, and gradually decreases 
with age, which reflects the natural history of disease. 
     Serum markers like acute phase reactants and various modulator of inflammation 
including cytokines were used to detect disease activity in the past.  A study (NSSYS) was 
performed comparing active Takayasu arteritis patients and healthy adult volunteers using 
various serological markers such as ESR, CRP, Tissue factor, vWF, tPA, ICAM-1, VCAM-1 
and thrombomodullin.  None of the markers was found reliable for the assessment of activity 
of the disease. 
1.2 Cytokines and matrix metalloproteinases: 
Elevated serum concentration of IL-6 and RANTES (regulated on activation,  normal 
T cell expressed and secreted) was noticed in all of the 18 studied active Takayasu arteritis 
patients by Marina-Noris et al114. 
Studies in patients have shown significantly elevated levels of both Il-6 and RANTES 
in the active form of Takayasu arteritis disease; T lymphocytes, NK cells and macrophages 
infiltrate large vessels because of chemoattractant activities of RANTES 115,116.  Immune 
trigger on the endothelium produces RANTES. Serum concentrations of IL-6 or RANTES 
are directly correlated with disease activity. 
Enzyme linked immunabsorbant assay (ELISA) was done for assessment of Il-6 and 
RANTES.  The level of IL-6 and RANTES correlated with the ESR but did not match the 
CRP level117. 
IL-6 and RANTES showed close correlation with Takayasu arteritis disease activity.  
So constant monitoring of these markers may helpful in immunosuppressive drugs dose 
adjustment. 
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Pentarixin 3 (PTK3)118 is secreted as pro-inflammatory response by immune and 
vascular cells.  It may be used as marker for detecting disease activity and is of importance in 
Takayasu arteritis patients.   
     Matrix metalloproteinases are zinc endoproteinases involved in inflammatory 
reactions and significant correlation has been noted between MMP-3 and MMP-9 levels and 
disease activity of Takayasu arteritis.  Serum level of MMP-2 MMP-3 was directly correlated 
with disease activity of Takayasu arteritis.  MMP-3/TIMP-1 ratio may be a useful marker for 
disease activity119. 
1.3 NIH (National institute of Health) criteria: 
Disease activity of Takayasu arteritis is defined by NIH as - 
New onset or worsening of at least 2 of the following four factors: 
1. Vascular inflammatory or ischemic symptoms: claudication, diminished or absent 
pulses and blood pressure in extremities. 
2. Increased level of ESR 
3. Abnormal angiogram. 
4. Fever, polyarthralgia and myalgia etc.  
Symptoms should not be because of another disease. 
NIH data showed that in about 50 percent of patients, clinical features of disease and 
serum level of acute phase reactants were not adequate to assess disease activity and so were 
not reliable enough for therapeutic decisions. The low sensitivity of NIH criteria is a 
limitation for diagnosing active disease120. 
 
1.4 Vasculitis assessment and Takayasu arteritis: 
 
A critical analysis of the utility of ESR  and CRP and other acute phase reactants 
levels suggested that they do not reliably identify active disease121. It is well established that 
vascular wall inflammation can persist and arterial lesions progress in presence of a normal 
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ESR or CRP levels or both122,123. So it is important that the treating physician does not rely on 
the acute phase reactants alone, and instead uses the data in combination with an assessment 
of patient’s symptoms and complete relevant physical examination as well.   
Assessment of disease activity is the first priority for clinicians treating new 
vasculitis. The commonly used methods for assessment of vasculitis are the well-validated 
activity score Birmingham Vasculitis Assessment Score (BVAS)124 and the damage score, 
VDI (Vasculitis Damage Index). BVAS was developed to collect a comprehensive index of 
disease involvement across 10 organ related symptoms and proved usefull in clinical trials of 
anti-neutrolphil cytoplasmic antibody-associated vasculitis125,126. The quantitative measures 
of disease severity provided by a BVAS score at presentationoften a guide to long-term 
prognosis127. 
 Measurment of vasculitis damage index (VDI) shows that scars that develop early in 
arteries have a poor prognosis128. Both the total VDI score and the number of organs involved 
contributes to fatality. But BVAS and VDI have low sensitivity for the large vessel vasculitis. 
The NIH or Kerr criteria are more commonly used to define active disease in patients 
with Takayasu arteritis129, and easily applied, are of limited scope and might lack sensitivity. 
The absence of validated assessment criteria for either disease activity or extent has a 
limitations on the further clinical trials and research and international collaborations. 
The Indian Rheumatology association vasculitis group tried to solve this shortcoming, 
initially validated BVAS and the vasculitis damage index in Indian patients130 and 
subsequently developed a specific Takayasu disease activity score and a damage index. 131,132. 
There is a need for clinical assessment tools for large vessel disease like Takayasu arteritis, 
which is seen more frequently in India. 
 
1.5 Disease Extent Index for Takayasu arteritis  (DEI.Tak) : 
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Disease Extent Index (DEI.Tak) was validated to analyze the actual disease pattern 
recorded in 145 cases from India133.  About 60% patients had overt cardiovascular disease. 
About 50% patients had scored for renal disease due to direct results of major artery disease. 
46% patients had systemic symptoms such as fever, headache, arthralgia and myalgia but 
weight loss was very uncommon in contrast to small vessel vasculitis.  Restricted large vessel 
involvement in Takayasu arteritis is truely reflected by DEI.Tak. Nearly 50% of  CVS cases 
showed pulseloss, followed by pulse inequality, bruit and claudication, pulse loss was 
commonly seen in brachialis in about a third of cases, after that radial, femoral and foot 
pulses least commonly involved. The two centres data from India was presented at 
international meetings134 and the DEI.Tak has since been used to describe in Turkish cases135. 
  
This index may be very useful for treatment plan and epidemiological analysis of the 
disease in various parts of the world. 
1.6 Indian Takayasu Activity Score (ITAS) : 
 
The Indian Takayasu Activity score was basically data based and taking the new 
disease items (occurring in the last three months), that were scored in DEI.Tak . The clinical 
relevance of ITAS scoring criteria was tested in Rheumatology clinics. Analysis of data 
showed that 5 organs based systems were not relevant in Takayasu arteritis, hence can be 
removed from an activity index. All individual items scored in <5% were examined and the 
majority are omitted. The resultant slimmed-down ITAS2010 (Indian Takayasu Activity 
Score) contains 43 items in 6 systems, is easy to use for clinical practise and extensively 
validated by IRVAS. 
Importance has been given to 7 items related to the major vessel involvement, that is 
most relevant clinically. Takayasu arteritis patients follow-up showed that ITAS reflects 
treatment response and disease flare-up as well. ITAS has been used in therapy trials in India 
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to assess patients on Mycophenolate mofetil and by the Italian group to study the effect of IL-
6 receptor blockage136. 
2. Radiological  imaging in Takayasu arteritis 
Imaging modalities used for diagnosis and assessments of disease activity are as 
follows: 
 
2.1 Conventional angiography: 
This is performed if an intervention or surgical procedures is planned, and 
provides descriptive anatomic information. 
2.2 MR angiography of aorta and large vessel : 
                 This has the advantages that arterial puncture and exposure to iodinated contrast 
and radiation are avoided and is the test of choice in young women and children. 
                  However differentiation between vasculitis and atherosclerosis is difficult, limited 
information of distal aortic branches is obtained and no detailed information about arterial 
wall anatomy is obtained. 
2.3 CT angiogram 
This is useful if MRI is contraindicated and provides information of aortic 
calcification and arterial wall thickness. 
2.4 PET:  With Fluorine – 18F Deoxyglucose. 
             This shows regional differences in utilisation of glucose, locates inflammatory 
regions and is a clinical tool for monitoring disease activity and treatment response137, 
however, no information about lumen size is obtained. 
Management of Takayasu’s Arteritis 
Treatment options in Takayasu arteritis patients are: 
1. Pharmacological 
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2. Surgical 
3. Recent – less invasive endovascular treatment such as angioplasty and 
endovascular aneurysmal repair (stent grafts). 
 
 
Medical therapy: 
            Antithrombotic & Antihypertensive drugs: 
 Aspirin therapy is advised to prevent thrombus formation and adequate                          
anti-hypertensive medications are advised to more than 60 percent of patients who have 
systemic hypertension. 
Corticosteroids: 
Used in acute phase of Takayasu  arteritis and angiographic improvement seen with 
long time steroid treatment. Efficacy of corticosteroid depends upon disease activity 
and extent of disease. Decrease in ESR and decreased intensity of inflammatory 
symptoms are noted with steroid therapy. 
Immunosuppressive drugs: 
Immunosuppressive drugs such as methotrexate, mycophenolate mofetil, cyclophosphamide 
or azathioprine are used in treatment of Takayasu arteritis. Side effects of 
Immunosuppressive drugs are the important determinant of choice of immunosuppressive 
drugs. 
 Tocilizumab – Humanized monoclonal antibody anti IL-6 receptor (IL-6R) antibody, 
rapidly improved clinical manifestations and laboratory parameters and partially reverted 
signs of vascular ischaemia in a patient with refractory TA138. 
Percutaneous tranluminal angioplasty (PTA) : 
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In inactive stenotic / occlusive aortic or arterial lesions, recanalization and stenting are 
an attractive treatment modality in Takayasu arteritis patients. Symptomatic stenosis of 70 to 
80 percent or a systolic gradient of more then 50 mm Hg are consider as a indications for 
PTA. 
Successful recanalization and stenting of carotid, subclavian and renal and peripheral 
arteries have been reported. Endovascular aneurysmal repair for dilated aortic lesions139 has 
also been reported. 
 
Surgical treatment: 
Before the availability of PTA and stents, surgery was the mainstay of treatment.  It 
still remains an option if lesions are diffuse and not suitable for angioplasty.  Kieffer et al140 
reported satisfactory early and long term outcome after surgical renal artery revascularization. 
Surgical procedures performed include bypass of the obstructed vessel, 
endarterectomy, resection and end-to-end anastomosis and aortic valve replacement. 
 
 
 
 
 
Material & Methods: 
• Observational study done in the Department of Cardiology, Christian medical college, 
Vellore, Tamil Nadu. 
Study Protocol: 
39 
 
• We studied 125 patients with Takayasu Arteritis who came to our centre for 
treatment.  
• All patients of Takayasu Arteritis seen in the Cardiology Department from July 2011 
to October 2012 were enrolled in this study.    
• We studied the demographic, clinical, diagnostic and angiographic profile of these 
patients.  
• Symptoms we looked for were constitutional symptoms, heart-related symptoms, 
systemic hypertension, neurological symptoms and upper & lower limb fatigue and 
claudication. 
• We evaluated our patients using different diagnostic criteria: clinical, ACR criteria 
and Indian Takayasu Activity score.  
• We also studied the angiographic profile and lesion characteristics in these patients, 
based on peripheral and coronary Angiograms.  
• We classified our patient into 3 groups based on inflammatory markers, active ( ESR 
more than 6 mm at one hour and CRP more than 20 mg/L), smouldering (either of 
ESR more than 20 mm at one hour or CRP more than 6 mg/L) and inactive (ESR  < 
20 mm at one hour and CRP < 6 mg/L) 
• We also studied the response of inflammatory markers (ESR and CRP) to 
immunosuppressive therapy and the response to interventional therapy by follow-up 
evaluations.  
 
  
Setting of the Study:   
• Setting      - Department  of Cardiology,  
    Christian Medical College,  
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                       Vellore, Tamil Nadu. 
• Cardiology Out patients and inpatients in cardiology wards. 
• Period of patient enrolment    - July 2011 to October 2012  
• Follow-up period   - October 2011 to October 2012  
• Data collection and analysis      - August 2012 to December 2012  
• Completion of study                           - December 2012.  
Outcome Measures  
• Demographic features  
• Clinical presentation  
• Angiographic profile  
• Follow-up results of treatment 
• Effects of immunosuppressive drugs on disease activity  
Sample size:  
 Based on previous data on Takayasus arteritis disease, it was expected that 60 to 80% 
of Takayasu arteritis patients would have significant cardiovascular signs and 
symptoms. 
 In order to estimate significant findings such as limb claudication, bruit, blood 
pressure and pulse asymmetry and angiographic findings, with a precision of 5% to 
10% sample size of 85 to 350 was required.  
• Keeping in mind the low prevalence of disease we have decided to take a sample size 
of approximately 125 patients which provided a precision of nearly 8%.  
 
Results: 
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 All categorical variables are expressed in the form of number and percentage, and 
continuous variables are expressed in the form of mean and standard deviation. The 
comparison of mean CIMT was across with disease activity (ESR > 20 mm in one hour and 
CRP > 6 mg/L) by using independent t – test.   
 
Table 1: Demographic features- 
 
 
Variables N (%) Age (m ± SD) BMI  (m ± SD) 
Male 28   (22) 34 ±15 21 ± 4.0 
Female 97   (78) 31 ±11 23 ± 5.0 
All Patients 125 (100) 32 ±12 23 ± 5.0 
 
Figure 1  
 
 
 
 
 
 
 
 
 
 
 
 
n = 125 
 
 
Gender distribution showed predilection for females with female-to-male ratio of 3.5:1. 
 
 
 
 
 
 
 
 
Figure 2 : Types of Takayasu arteritis – 
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n = 125 
 
 
Type V Takayasu arteritis was most common type in the present study and comprised 44% of  
 
total study population followed by type I, type III, type IV and type II. 
 
Table 2 : Cardinal Symptoms  
 
Symptoms      Present N (%) 
Fatigue  62 (50%) 
Fever  17 (14%) 
Weight  loss  23 (18%) 
Myalgia 23 (18%) 
Arthralgia 19 (15%) 
All cardinal symptoms 42 (34%) 
Any cardinal symptoms  123 (98%) 
 
About 1/3rd of patients had cardinal symptoms, of which fatigue, weight loss and myalgia 
were the most common. 
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Table 3 : Heart related symptoms  
 
Symptoms           Number (%) 
Exertional dyspnoea 56 (45%) 
Paroxysmal  nocturnal dyspnoea 3 (2%) 
Orthopnea  5 (4%) 
Pedal oedema 8 (6%) 
Angina 13 (10%) 
Palpitations  22 (18%) 
Any heart related symptoms  62 (50%) 
 
 
Heart related symptoms are noticed in  half of the patients, out of which exertional dyspnoea,  
 
palpitations and angina were commonest symptoms. 
 
Figure 3: Neurological Symptoms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 n=125 
 
 
 
 
 
 
 
About 40% of patients had neurological symptoms and of which giddiness, blurred vision 
and syncope were the commonest. 
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Table 4: Mesenteric Symptoms  
     
Symptoms           Number (%) 
Post prandial abdominal pain  10 (8%) 
Anorexia  10 (8%) 
Weight loss 10 (8%) 
All Mesenteric symptoms  10 (8%) 
 
 
Table 5: Renal Symptoms 
 
Symptoms            Number (%) 
Systemic hypertension   75 (60%) 
Renal failure  3 (2%) 
Any renal symptoms  46 (37%) 
 
About 60% of the patients had hypertension and renal artery stenosis was angiographically  
 
seen in 48% of cases. 
 
Table 6: Upper Limb and Lower Limb Symptoms 
 
Symptoms  Number (%) 
Upper Limb Claudication  
           Right 
 
20 (16%) 
           Left 27 (22%) 
           Bilateral 27 (22%) 
Lower Limb Claudication 
           Right 
 
7 (6%) 
           Left 7 (6%) 
           Bilateral 33 (26%) 
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Table 7: Miscellaneous Symptoms 
 
 
Symptoms Present 
Headache  55(44%) 
Abortion  16(13%) 
Past Tuberculosis  11(9%) 
Epistaxis 8 (6%) 
Any miscellaneous symptom 54 (43%) 
 
 
 
Table: 8 Clinical Diagnostic Criteria 
 
 
Clinical Criteria N                                  % 
Major Criteria 
Typical sign and symptoms (>1/12 months) 
 
85                              68% 
Imaging lesion in mid left subclavian artery 75                              60% 
Imaging lesion in mid right subclavian artery 56                              45% 
Minor Criteria 
ESR (>20 mm) 
 
69                              55% 
Carotid artery tenderness 19                              15% 
Blood Pressure (Brachial BP> 140/90,Popliteal BP > 160/90) 52                              42% 
AR by auscultation, echo or angio 19                              15% 
Pulmonary artery lesion 7                                  6% 
Left common carotid artery lesion 52                               42% 
Distal brachio cephalic lesion 15                               12% 
Descending thoracic aorta lesion 28                               22% 
Abdominal aorta lesion 38                               30% 
Coronary artery  lesion 17                               14% 
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Figure 4: Diagnostic criteria used. 
 
 
 
 
 
95% of the patients met clinical criteria and 89 % patients had ACR score ≥3, all of the  
 
study patients met at least one of the criteria (either clinical or ACR) used for the diagnosis. 
 
 
 
Table 9: Disease Activity at first visit 
 
  
Symptoms Present Absent 
ESR > 20mm at 1 hour   97 (78%) 28(22%) 
CRP > 6 mg / L 69(55%) 56(45%) 
Both 53(42%) 72(58%) 
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Figure 5: 
 
 
 
. 
 
 
Disease activity at first visit –  78% of patients had ESR > 20 mm at 1 hour and 55% 
 
of patients had CRP >6 mg / L at first visit, 42%  of patients had  elevation of both markers 
  
(ESR > 20 mm in 1 hour and CRP > 6 mg/L) at first visit. 
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Figure: 6 Indian Takayasu Activity Score (ITAS) at First Visit 
 
 
 
At first visit 95% of patients showed ITAS score ≥ 3. 
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Table 10: Angiographic profile (n = 125) 
 
Zone Vessel Involved            Number (%) 
 
 
Aorta 
Ascending  Aorta 18 (14%) 
Arch of Aorta  4 (3%) 
Descending Aorta  28 (22%) 
Abdominal Aorta  38 (30%) 
 
 
 
 
Arch Branches 
Innominate Artery  15 (12%) 
Rt. Subclavian  Artery  56 (45%) 
Lt. subclavian  Artery 75 (60%) 
Rt. Vertebral Artery  9 (7%) 
Lt. Vertebral Artery 15 (12%) 
Rt. Common Carotid Artery  33 (26%) 
Lt. Common Carotid Artery 52 (42%) 
Rt. Internal  Carotid Artery 3 (2%) 
Lt. Internal Carotid Artery 3 (2%) 
 
 
Visceral Aortic Branches 
Celiac Artery  54 (43%) 
Superior Mesenteric Artery  35 (28%) 
Inferior Mesenteric Artery 2 (2%) 
Right Renal Artery  15(12%) 
Left Renal Artery  19(15%) 
Bilateral Renal Artery 26(21%) 
 
Iliac and Femoral artery   
Iliac Artery 6 (5%) 
Femoral Artery 2 (2%) 
 
 
 
Table 11: Coronary and pulmonary artery involvement 
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Vessel Involved   Number (%) Patients Studied 
Coronary artery  17 (14%) 115 
Pulmonary artery  7 (6%) 105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Angiographic Involvement of Renal arteries 
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Angiographically right and left renal artery stenosis seen in 12% and 15% respectively, while 
 
 bilateral renal artery involvement was found in 21% of patients. 
 
Table 12 : Disease Activity in follow-up 
 
 
Disease Activity   Active Smouldering  Inactive  
Disease Activity at  
1st visit 
55 (45%) 51 (41%) 19(15%) 
Disease Activity on   
Last follow up  
30 (24%) 51 (41%) 40 (32%) 
 
 
Active disease is define as ESR more than 20 mm at one hour and CRP more than 6 mg/L, 
smouldering disease if either of ESR more than 20 mm at one hour or CRP more than 6 mg/L  
and inactive  disease consider when ESR  < 20 mm at one hour and CRP < 6 mg/L. 
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Figure 8: Treatment outcomes 
 
 Response to medical treatment at follow-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
About 1/3rd of patients showed good response to immunosuppressive medications and about  
 
half of the patients showed satisfactory disease activity parameters.  
 
 
Good          - Both activity markers found low  
                     (ESR  < 20 mm at one hour & CRP < 6mg/L). 
Satisfactory- One disease activity markers found low and other was elevated. 
 
                     (if either of ESR more than 20 mm at one hour or CRP more than 6 mg/L)  
  
Poor           - Both disease activity markers were found elevated 
 
               (ESR more than 20 mm at one hour and CRP more than 6 mg/L) 
 
 
 
Figure 9: Response to intervention treatment at follow-up 
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Total intervention done in 119 patients in which about 40% of patients showed good  
 
response to previous intervention and 26% of patients showed satisfactory angiographic 
 
results in follow up angiogram. 
 
We defined response of intervention treatment based upon follow-up angiogram 
 
Good          - Patent deployed stents, repeated procedures not required and only minor     
 
                     restenosis (< 50% of vessel lumen diameter) seen. 
 
Satisfactory-Significant restenosis (> 50% of vessel lumen diameter) or occlusion of one  
 
                     stent or ≤2  repeat procedures required. 
 
Poor            -Occlusion of ≥ 2 stents and  > 2 repeat procedures in follow-up. 
 
 
 
 
 
 
54 
 
Table 13(A): Correlation of Right Carotid Intima-Medial 
Thickness and Disease activity  in angiographically normal 
carotid arteries patients.  
 
 
 
Variables CIMT (x  ±  SD) P value 95% CI 
Active Disease 
Smouldering Disease 
Inactive Disease 
0.87 ± 0.29 mm 
0.67 ± 0.16 mm 
0.65 ± 0.16 mm 
0.029* 0.02-0.37 
1.000* -0.19-0.23 
0.043* -0.42- -0.01 
 
(* Adjusted for Bonferrini  Correction) 
 
 
 
 
Table 13 (B): Correlation of Left Carotid Intima-Medial 
Thickness and Disease activity in angiographically normal carotid 
arteries patients. 
 
 
Variables CIMT (x  ±  SD) P value 95% CI 
Active Disease 
Smouldering Disease 
Inactive Disease 
0.93 ± 0.25 mm 
0.64 ± 0.18 mm 
0.65 ± 0.17 mm 
<0.000* 0.12-0.45 
1.000* -0.20-0.19 
<0.002* -0.48- -0.09 
 
(* Adjusted for Bonferrini  Correction) 
 
 
For continuous variables we used the independent T-test. 
 
We also used ANOVA test to compare the three patients groups CIMT and we found there is 
a statistically significant (p-0.029) difference in mean CIMT of three groups and we used the  
Bonferrini correction to find which group is contributing more and we found active disease 
group have higher CIMT. 
 
 
 
 
Table 14 (A): Correlation of  ESR > 20 mm in one hour and CRP 
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 > 6 mg/Lt and Right Carotid Intima-Medial Thickness 
 
 
ESR > 20 and CRP > 6 mg/L CIMT (x ± SD) P value 95% CI 
Absent 0.66 ± 0.16 mm <0.005 0.07 – 0.36 
Present 0.88 ± 0.29 mm 
 
 
 
Table 14 (B): Corelation of  ESR > 20 mm in one hour and CRP > 
 
 6 mg/Lt and Left Carotid Intima-Medial Thickness 
 
 
ESR > 2 and  CRP > 6mg/L CIMT (x  ± SD) P value 95% CI 
Absent 0.65  ± 0.17 mm <0.000 0.16-0.43 
Present 0.94  ± 0.25 mm 
 
 
We found statistically significant (p<0.000) increased CIMT value >0.90 mms in active 
Takayasu arteritis patients in present study. 
 
 
 
 
 
 
DISCUSSION: 
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The age of presentation of  Takayasu arteritis in the present study was 32±13 years.  
In a large series of 107 patients, from Japan mean age at presentation was 29 years141 while in 
a study of 88 patients from our country142 the mean age at symptom onset was 24±9 years 
and mean age at diagnosis was 28±10 years. 
 In present study female patients comprised 78% of the study population, with a 
female-to-male ratio of 3.5:1, which was comparable to previous studies which showed 
predilection for females with a wide geographical variation.  In Japan female-to-male ratio 
was noticed 8:1, in Mexico 5:1 and in India 4:1143 and Israel 1.2:1. In the patient series of 
Panja et al144 female-to-male ratio was found 6.4:1. 
           The most common type of Takayasu arteritis seen in our study was type V (44%), 
followed by type I (28%) of total population, but this finding does not match with other 
studies.  Agarwal et al145 reported type III (53%) is most common among north Indian 
patients and in a large series data of Panja et al144 showed type IV (36%) is most common 
type of Takayasu arteritis in patients belonging to Eastern India and Bangladesh. 
About 1/3rd of the patients in our study showed various cardinal symptoms, of which 
fatigue (50%) was the most common symptom, these finding correlate with other studies in 
which non-specific symptoms like fever, night sweat, malaise, weight loss, arthralgia, 
myalgia and mild anaemia were common symptoms146, usually associated with the early or 
pre-pulseless phase. 
In the present study, about 50% of Takayasu arteritis patients had heart-related 
symptoms of which exertional dyspnoea and palpitations were the most common symptoms.  
Giddiness was the most common neurological symptom noticed.  About 13% of patients had 
a history of stroke, which was similar to European Takayasu arteritis patient series in which, 
10-20% of patients have ischemic stroke or TIA147. 
According to Morwaki et al148 Japanese patients have higher rate of neurological 
complications, because more frequent aortic arch involvement as compared to Indian patients 
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in whom abdominal aorta and renal arteries are more commonly involved149.  Takayasu 
arteritis patients can rarely present with stroke as their first symptom150. Hypertension and 
cerebral ischemia can secondarily lead to postural dizziness, seizures and amaurosis. 
          A small number of patients (about 8%) showed mesenteric symptoms in the form of 
post-prandial abdominal pain, anorexia and weight loss. About 60% of our study patients had 
systemic hypertension, which was similar to previous studies in which about 33-83% of 
patients were found hypertensive151,152,153. A common cause of systemic hypertension in 
Takayasu arteritis patients is renal artery stenosis, other contributory factors being atypical 
coarctation, decreased baroreceptor reactivity and decreased aortic capacitance. 
In patients with Takayasu arteritis as the inflammatory process progresses and 
gradually leading to stenosis and occlusion, more characteristics clinical features appear but 
at the same time the development of collateral circulation may ameliorate some features. 
           In present study upper limb symptoms was documented in the form of right upper limb 
claudication (16%), left upper limb claudication (22%) and bilateral upper limb claudication 
in 22% of patients, while bilateral lower limb claudication noticed in 26% of patients.  This 
data matches the study of Panja154 et al series which showed intermitant limb claudication in 
25% of  Takayasu arteritis patients. 
 In this study for establishing the diagnosis of Takayasu arteritis we used clinical and 
American College of Rheumatology criteria155. In the present study more than 95% patients 
met clinical criteria and which is comparable to modified criteria by Sharma et al which has a 
sensitivity of 92.5%.  89% of patients found to have ACR score ≥ 3 which is comparable to 
previously measured sensitivity of 91%. ITAS score was calculated > 3 in 95% of patients.  
 We assesed the disease activity of our study patients by using ESR (> 20mm at 1 
hour) and CRP (> 6 mg/L). ESR > 20 mm at 1 hour was found in 78% of patients and CRP > 
6 mg/L was reported in 55% of patients;  42% of patients was found active disease (both) 
state in the first visit.  
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 We did conventional angiography in all 125 patients which  showed that the, most 
frequently affected vessel was the subclavian artery, aortic involvement was predominantly 
seen at the abdominal level, greater involvement of left subclavian comared to right 
subclavian artery and greater involvement of left common carotid artery as compared to right 
common carotid artery. 
 Reno-vascular hypertension is a frequent finding in Takayasu arteritis and was seen in 
50% patients156.  Hypertension in Takayasu arteritis patients is mainly due to renal artery 
stenosis and other contributory factors such as atypical coarctation  and reduced elasticity of 
the arterial wall.  Renal artery stenosis causes decreased renal perfusion leading to excess 
secretion of  renin and increased level of aldosterone and finally causes salt and water 
retention and increased blood pressure. In our study we found 15% involvement of right renal 
artery and 19% involvement of left renal artery, while in 26% of patients bilateral renal 
arteries are involved. 
 Coronary artery involvement in Takayasu arteritis is rare and previous study by 
Kumar157 et al mentioned about 9% to 11% coronary artery involvement in Takayasu arteritis 
presenting as stenosis, occlusion or coronary artery aneurysm formation and mostly involving 
the ostia of the coronary arteries. In our  study we did coronary angiography in 116 patients, 
out of which 17 (14%) patients showed coronary artery involvement which  is marginally 
higher than the previous studies. 
 In Takayasu arteritis diseases characteristically involved systemic and pulmonary 
arteries. Yamada158 et al found 70% pulmonary artery involvement in the small series of 30 
patient and noticed that the extent of arteritis in the major branches of the aorta appear to 
correlate with pulmonary artery involvement.  
 Johnston et al  described 14 - 100% pulmonary artery involvement in Takayasu 
arteritis patients based upon method used to described the pulmonary vasculature. Sharma159 
et al studied pulmonary arterial anatomy in Takayasu's arteritis patients by using intravenous 
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digital subtraction angiography (IV-DSA) and found angiographically evident pulmonary 
arterial involvement in 14% patients and out of which 1/3rd of cases have abnormal chest 
radiographs. Takayasu pulmonary artery vasculopathy shows little correlation with the 
systemic pattern of arterial involvement. 
 Previous studies have shown increased carotid intima - medial thickness (CIMT) in 
inflammatory conditions, including Takayasu arteritis160,161. 
 In the present study we found the statistically significant (P=0.014) higher mean 
CIMT >0.9mm in active Takayasu arteritis patients with angiographically normal carotid 
arteries, as compared to inactive Takayasu arteritis patients. 
 In the present study we also analysed the  response to medical treatment using 
assessment of disease activity by ESR and CRP at first visit and last follow up visits till 
December – 2012, and found that about 1/3rd  of patients had good and 40% of patients had 
satisfactory response to medical management; the remaining had  persistently active diseases. 
 Based upon follow-up peripheral angiogram we found that about 40% of patients have 
good results (deployed stent found patent, follow-up procedure not required or minor ISR  
seen) and 1/3rd patient showed satisfactory results of interventions and 30% patients are in 
our follow-up for whom results will seen over time. 
 
 
 
 
 
CONCLUSION 
1. Mean age at presentation of Takayasu arteritis patients in this study was 32±13 years. 
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2. The disease showed a predilection for females, with female : male ratio of  3.5:1. 
3. Type V Takayasu arteritis was most common (44%) followed by Type I (28%) and   
             Type III (12%) disease. 
4. A third of Takayasu arteritis patients had Cardinal symptoms. 
5. Half the patients in this study had heart-related symptoms of which exertional  
            dyspnoea was most common. 
6. About 40% of patient had neurological symptoms, of which giddiness, blurred vision  
            and syncope were commonest. 
7.     Almost 60% of the study patients were found hypertensive and renal artery stenosis                   
was angiographically seen in 48 % of cases. 
8. Upper limb claudication presented as right or left or bilateral upper limb claudication  
            with equal frequency of about 25 %. 
9. Bilateral lower limb claudication was more common (26%), as compare to isolated   
            right or left lower limb claudication (6% each). 
10. Headache was a common symptom and was found in 44% of patients. 
11.   95% of patients met clinical criteria and 89% of patients had ACR score ≥3 and all of        
           the study patients met atleast one diagnostic criteria, ITAS score was found≥3 in 95%      
           of patients 
12. Angiographic profile of   Takayasu arteritis disease in this study showed significantly  
            more involvement of arch vessels compare with abdominal aorta and it’s branches. 
13. Coronary artery involvement is seen in 14% and pulmonary artery involvement in 6%  
            of patients. 
14. Almost half the patients were in active state of disease at first visit, this decreased to  
            25% at last follow up. 
 15. A significantly higher proportion of patients with active disease had CIMT > 0.9mm. 
 16. A third of patients showed good and half the patients showed satisfactory response to   
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medical treatment. 
 17.        Half the patients had good response to intervention and one third patients showed     
             satisfactory response to intervention in this study. 
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TAKAYASU’S ARTERITIS – Demographic Features, Diagnosis, 
 
Clinical Presentation and Angiographic Profile  
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CASE STUDY PROFORMA 
 
 
Case Study Serial No. ____________  CMC H.No - 
Patient Name   : ________________________ 
Father’s / Husband’s Name : ________________________ 
Age     : ____________ 
Sex     : ____________ 
Year of Birth    : ____________ 
Body Weight    : ____________ Kg. 
Height     : ____________ cm. 
BMI     : ____________ Kg. / m2BSA 
Marital Status   : Married / Unmarried 
Contact No. & Address   
Mobile 1    : _________________________  
Mobile 2    : _________________________ 
Landline 1    : _________________________ 
Landline 2    : _________________________ 
Email ID    : 
Address    : _________________________________ 
      _________________________________ 
      _________________________________ 
State     : 
Date of Enrolment   : __________________ 
Type of TA    : ________ 
Year of onset of symptoms  : ________ 
 
SYMPTOMS DETAIL: 
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Symptom Status   : Asymptomatic 
      Symptomatic 
      Unknown  
 
Constitutional Symptoms   : None 
      Fatique / Malaiase 
      Fever 
      Weight Loss 
      Myalgia / Arthralgia 
      Multiple 
 
Heart Related   : None 
      ExertionalDysnoea 
      PND / Orthopnea / Pedal Edema 
      Angina 
      Palpitation 
 
Neurological    : None 
      Dizziness / Giddiness 
      Syncope 
      TIA 
      Stroke 
      Amaurosis 
      Blurred Vision 
      Neek Pain / Carotido-dynia 
      Seizure 
      Multiple 
 
Mesenterie    : None 
      Postprandial abd.pain 
      Anorexia / Weight loss 
 
 
Renal / Aortic   : None 
      HTN 
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      Renal Failure 
Upper limbs symptoms  : None 
      Right upper limb fatigue 
      Right upper limb claudication 
      Left upper limb fatigue 
      Left upper limb claudication 
      B/L upper limb fatigue 
      B/L upper limb claudication 
Lower Limbs symptoms  : None 
      Right Lower limb fatigue 
      Right Lower limb claudication 
      Left Lower limb fatigue 
      Left Lower limb claudication 
      B/L Lower limb fatigue 
      B/L Lower limb clandication 
      Critical Isehemia 
Miscellaneous   : None 
      Head ache 
      Abortion 
      GF Bleeding 
      Tuberculosis 
      Epistaxis 
 
CLINICAL DIAGNOSTIC CRITERIA: 
 
1. Obligatory criteria – Age < 40 years 
 Typical Sign and Symptoms for > 1 / 12 : Y   /   N  /  Unknown 
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2. Major Criteria 
 Imaging Lesion in  Mid LSCA  : Y   /   N  /  Unknown 
           Mid RSCA  : 
 Total Major Criteria    : 1  /  2  /  3  / None 
3. Minor Criteria 
 ESR > 20     : 1  /  2  /  3  / None 
 Carotid artery Tenderness   : 1  /  2  /  3  / None 
    
   Brachial BP > 140/90 
   Popliteal BP > 160/90 : 1  /  2  /  3  / None 
 AR by auscultation, echo or angio : 1  /  2  /  3  / None 
 P A lesion     : 1  /  2  /  3  / None 
 LCCA lesion     : 1  /  2  /  3  / None 
 Distal Brachio cephalic lesion  : 1  /  2  /  3  / None 
 Desc.Thoracie aorta lesion  : 1  /  2  /  3  / None 
 Abd. Aorta lesion    : 1  /  2  /  3  / None 
 Coronary Artery lesion   : 1  /  2  /  3  / None 
 Total Minor Criteria    : 1  /  2  /  3  / None 
 Clinical Criteria Met    : (2 Major /1 Major+2 Minor/4 
Minor)  
Y / N / Unknown 
 
 
 
 
 
 
 
ACR CRITERIA: 
 
 
Extremity Claudication   : 1  /  2  /  3  / None 
 
Decreased BA pulsation   : 1  /  2  /  3  / None 
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10 mmHg diff. In SBP both arms  : 1  /  2  /  3  / None 
 
Arteriographic narrowing   : 1  /  2  /  3  / None 
 
SCA or abd aortic bruit   : 1  /  2  /  3  / None 
 
Age at onset of ≤ 40 yrs.   : 1  /  2  /  3  / None 
 
Total score out of 6    : Zero / One / Two / Three / Four / Five 
/ Six 
 
ARA Criteria met (>3)   : 1  /  2  /  3  / None 
 
 
 
Bilateral Carotid Artery Doppler Study: 
CIMT Right -   
CIMT Left   - 
 
CLINICAL CRITERIAL MET: 
 
 Yes   C+  -  Y/N/UK 
 No   P+   -  Y/N/UK 
 Unknown   
 
ACR CRITERIA MET: 
 
 Yes 
 No 
 Unknown 
 
 
 
 
 
 
 
 
 
ITAS SCORE:  
 
 Extent of Disease (Angiographic Profile) 
Aorta 
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Part Lesion Characteristic Intervention Done Y/N (PTA/Stent-Dt) 
Asc. Aorta   
Arch Aorta   
Desc. Aorta   
Abd. Aorta   
  
 
Innominate 
 
RSCA 
RBxA 
RBrA 
RVA 
RCCA 
(Ostial) 
RCCA 
(Rest) 
RICA 
RECA 
Prox. Mid. Distal  
 
   LSCA 
LAxA 
LBrA 
LVA 
LCCA 
(Ostial) 
LCCA 
(Rest) 
LICA 
LECA 
Prox. Mid Distal 
LC ID LC ID LC ID LC ID LC ID LC ID 
            
            
            
            
            
            
            
            
            
            
 
 Part & Lesion Characteristics Intervention Done Date 
Coronary Arteries   
Pulmonary Arteries   
Celiac Artery   
S.M.A.   
I.M.A.   
 
RT Renal 
Artery 
L.C. I.D LT Renal 
Artery 
L.C. I.D 
Upper   Upper   
Lower   Lower   
Iliac   Femoral   
Common Iliac   Common   
Ext.Iliac   SFA   
 
Lesion Characteristics 1 – Irregularity / Calcium       Intervention Done        P – PTA 
(L.C.)                           2 – Stenonis                            (I.D)                             S – Stent 
                                     3 – Occlusion 
                                     4 – Aneurysm 
 
 
 
 
Baseline Data: 
 
Baseline  ESR 
 CRP 
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Baseline Activity 
Active: ESR   > 20 
 CRP > 6 
 
Smouldering: ESR > 20 
    (or) 
 CRP > 6 
 Not both 
Inactive: ESR ≤ 20 
       + 
 CRP ≤  6 
 
Drugs: None 
 Prednisolone 
Azathioprine 
Methotrexate 
Prednisolone + Azathioprine 
Prednisolone + Methotrexate 
Azathioprine + Methotrexate 
Prednisolone + Azathioprine + Methotrexate 
Deflezocort 
MMF 
Deflezocort + MMF 
Deflezocort + Azathioprine 
Prednisolone + MMF 
Deflezocort + Methotrexate 
 
SUMMARY OF CASE REPORT: 
 
• Type of Takayasus’s Arteritis - 
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• Response of ongoing Medical management - 
• Results of Intervention in follow up (Angiographic profile) - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACR CRITERIA: 
 
 
Extremity Claudication   : 1  /  2  /  3  / None 
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Decreased BA pulsation   : 1  /  2  /  3  / None 
 
10 mmHg diff. In SBP both arms  : 1  /  2  /  3  / None 
 
Arteriographic narrowing   : 1  /  2  /  3  / None 
 
SCA or abd aortic bruit   : 1  /  2  /  3  / None 
 
Age at onset of ≤ 40 yrs.   : 1  /  2  /  3  / None 
 
Total score out of 6    : Zero / One / Two / Three / Four / Five 
/ Six 
 
ACA Criteria met (>3)   : 1  /  2  /  3  / None 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX - 2 
 
ITAS  – Indian Takayasu Activity Score 
Tick Box only if abnormality is present (new or worse) within past 3 months.   
Tick box only if abnormality is ascribed to current, active vasculitis. 
Visit Date   : 
Patient  ID 
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1. SYSTEMIC                     
 None 
Malaise/Wt. Loss>2Kg 
Myalgia/Arthralgia/Arthritis. 
Headache 
Fever 
 
2. MUCOUS MEMBRANES 
 None  
Present 
 
3. EYES 
 None 
Blurred Vision 
Sudden Vision Loss 
Other 
 
4. CHEST 
 None 
Persistent Cough 
Dyspnea/Wheeze 
Hemoptysis/Hemorrhage 
Massive Hemoptysis 
Respiratory Failure 
 
    5. ABDOMEN 
  None  
    Severe Abdominal Pain   
    Bloody Diarrhea    
Gut Perforation/Infarct   
 
6. RENAL 
  None  
Hypertension (Diastole >90)    
     “”          Systolic >140   
Proteinuria (>1+/0.2g/24H)     
Hematuria (>1+/10RBC/ml)    
Creatinine (1.4-2.73 mg/dl)    
Creatinine (2.75-5.5mg/dl)    
Creatinine (>5.5 mg/dl)     
Rise in creatinine>30% or 
> 25% fall in creatinine clearance.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Nervous System 
  None 
Organic Confusion/Dementia   
Seizures (not hypertensive)     
Stroke      
Syncope      
Cord Lesion     
 
   
8. Genitourinary System 
 None 
Sexual Impotence     
Abortions      
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9. CARDIOVASCULAR SYSTEM      
 None  
Bruits (see 9a) 
Pulse Inequality (See 9b) 
 
New Loss of Pulses (See 9c) 
New Loss of pulses with threatened loss of limb. 
 
Claudication (See9d) 
Carotidodynia 
 
Aortic Incompetence 
Pericardial Pain/Rub 
Ischemic Cardiac Pain 
Congestive Cardiac Failure 
 
 
 
  
 
 
 
 
 
 
10. Other Vasc items:  11. Physician Global Opinion (Active / Grumbling or persistent / 
Inactive): 
 
 
 
12.  ESR :             CRP:         
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSENT FROM 
 
 
Cardiology Opinion/Tests  
No Active Vasculitis    
Pericarditis     
Myocardial Infarct/Angina    
Cardiomyopathy
9a. Bruits   R  L 
Carotid      
Vertebral      
Subclavian     
Renal      
Abdominal    
Inguinal      
9b. Pulse and BP Inequality 
Present     
9c. Pulse Loss 
Carotid      
Subclavian     
Brachial      
Radial      
Femoral      
Popliteal      
Posterior Tibial     
DorsalisPedis     
9d. Claudication 
Arm     
Leg           
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Study Title:  TAKAYASU’S ARTERITIS – Demographic Features, Diagnosis Clinical  
Presentation and Angiographic Profile  
Study Number: 
Subject’s Initials:____________ Subject’s Name:___________ 
Date of Birth /Age:_________ 
Please initial Box 
(Subject) 
(i) i confirm that I have read and understood the information sheet dated ________ for the 
above study and have had the opportunity to ask questions.[ ]  
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [ ] 
(iii) I understand that the Sponsor of the Clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission to 
look at my health records both in respect of the current study and any further research that 
may be conducted in relation to it, even if i withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
Representative:______________ 
Date: ______/______/________ 
Signatory’s Name: _______________________________ 
 
Signature of the Investigator:_______________________ 
Date: ______/______/________ 
Study Investigator’s Name: __________________________ 
 
Signature of the Witness:____________________________ 
Date: ______/______/________ 
Name of the Witness: _______________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
GLOSSARY FOR THE MASTER DATA SHEET 
 
A – Case No. 
B – pt. Name 
C – Hosp. No. 
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D – Age 
E  - Sex of the patient 
      1 = Male, 2= Female 
F – BMI = Body Mass Index. 
G – Type of TA 
H – Year of onset of the symptoms   
I – Symp_Status 
     0= Asymptomatic, 1 = symptomatic 
J – C_ Symp_None (Constitutional symptom None) 
      0= Constitutional symptom present , 1=Constitutional symptom absent. 
K – C.Symp_Fatigue 
       0=Fatigue absent , 1= Fatigue present. 
L – C.Symp_Fever 
       0= Fever absent , 1= Fever present. 
M – C.Symp_Wt. Loss 
       0=Wt. loss absent , 1= Wt loss present. 
N – C.Symp_Myalgia 
       0=Myalgia absent , 1= Myalgia present. 
O – C.Symp_Arthralgia 
       0=Arthralgia absent, 1=Arthralgia present. 
P – H.RelatedSymp_none 
      0= H related symptoms present, 1= H related symptoms absent. 
Q – H.Related_EDysnoea 
      0= Effort Dysnoea absent, 1=Effort Dysnoea present. 
R – H. Related PND 
       0=PND absent, 1=PND present. 
S -  H. Related Orthopnea 
      0=Orthopneaabsent , 1=Orthopnea present 
T – H.Related_Pedaledema 
        0=Pedal edema absent, 1=Pedal edema present. 
U – HRelated_angina 
       0=angina absent, 1=angina present. 
V – H Related_Palpitation 
        0=Palpitation absent , 1=Palpitation present. 
W – Neurological_None 
        0=Neurological symptoms present, 1=Neurological symptoms absent. 
X – Neurological_Giddiness 
       0=Giddiness absent, 1=Giddiness present. 
Y – Neurological_Syncope 
       0=Syncope absent, 1=Syncope present. 
Z – Neurological_TIA 
       0=TIA absent , 1=TIA present. 
AA – Neurological_Stroke 
       0=H/O stroke absent, 1=H/O stroke present. 
AB – Neurological_Blurredvision 
        0=Blurred vision absent, 1=Blurredvision present. 
AC – Neurological_Neckpain 
        0=Neck pain absent, Neckpain present. 
AD – Neurological_Seizure 
       0=Seizure absent, 1=Seizure present. 
AE – Mesenteric_Postabdpain 
       0=Post prandabd pain absent 1=Post prandabd pain present. 
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AF – Mesenteric_Anorexia 
       0=Anorexia absent, Anorexia present. 
AG – Mesenteric Wt. loss 
       0=Wt. loss absent, 1=Wt. loss present. 
AH – Renal_None 
       0=Renal symp present, 1=Renal symp absent. 
AI – Renal_HTN 
       0=HTN absent, 1=HTN present. 
AJ – Renal_Renal failure 
        0=Renal failur absent, 1=Renal failure present. 
AK – UL_None 
          0=Upper limb symptoms present, 1=Upper limb symptoms absent. 
AL – UL_RULF 
          0=Rt Upper Limb Fatigue absent, 1=Rt Upper Limb Fatigue present. 
AM – UL_RULC 
          0= Rt Upper Limb claudication absent, 1=Rt Upper Limb claudication present. 
AN – UL_LULF 
          0=Lt Upper Limb Fatigue absent, 1= Lt Upper Limb Fatigue present. 
AO – UL_LULC 
          0=Lt Upper Limb claudication absent, 1=Lt Upper Limb claudication present 
AP – UL_BULF 
          0=B/L Upper Limb Fatigue absent, 1=B/L Upper Limb Fatigue present. 
AQ – UL_BULC 
          0=B/L Upper Limb claudication absent,1=B/L Upper Limb claudication present. 
AR – LL_None 
          0=Lower Limb symptoms present, 1=Lower Limb symptoms absent. 
AS – LL_RLLF 
          0=Rt lower limb fatigue absent, 1=Rt lower limb fatigue present 
AT – LL_RLLC 
           0=Rt lower limb claudication absent,1=Rt lower limb claudication present. 
AU -- LL_LLLF 
            0=Lt Lower Limb Fatigue absent, 1=Lt Lower Limb Fatigue present 
AV – LL_LLLC 
           0=Left Lower Limb claudication absent,1=Left Lower Limb claudication present. 
AW -- LL_BLLF 
            0=B/L Lower Limb Fatigue absent, 1=B/L Lower Limb Fatigue present. 
AX -- LL_BLLC 
             0=B/L Lower Limb Claudication  absent, 1=B/L Lower Limb claudication present. 
AY --Misc_None 
             0=Miscallenious symptoms present,1=Miscallenious symptoms absent. 
AZ --Misc_Headache 
             0=Headache absent,1=Headache present. 
BA --Misc_Abortion 
 
         0=H/O - Abortion absent,1-H/O - Abortion present. 
BB -Misc_TB 
        0=H/o TB absent , 1= H/o TB present. 
BC --Misc_Epist. 
        0= H/o Epist. Absent, 1=H/o Epist. Present. 
BF --ClinicalCr.Met 
        0=Clinical Cr. Not Met, 1=Clinical Cr.Met 
BG --ACR Cr. Met 
         0=ACR Cr. not met, 1=ACR Cr. met. 
BH – Total ACR score. 
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BI  -- ITAS score. 
BJ – ESR. 
BK – CRP 
BL  -  ESR_CRP 
BM -  cIMT Rt 
BN  – Mean Rt CIMT 
BO – cIMT Lt 
BP -- Mean Lt CIMT 
BQ –Aorta_Ascending 
        0=Ascending aorta not involved,1=Ascending aorta involved. 
BR--Aorta_Arch 
        0=Arch aorta not involved, 1=Arch aorta involved. 
BS—Aorta_Desc 
        0=Descending aorta not involved,1=Descending aorta involved. 
BT—Aorta_Abd 
        0=Abdominal aorta not involved,1=Abdominal aorta not involved. 
BU—Innominate involvement. 
        0=Innominate not involved,1=Innominate  involved. 
BV –RSCA involvement 
        0=RSCA not involved, 1=RSCA  involved, 
BW—LSCA lesion 
        0=LSCA not involved, 1=LSCA involved. 
BX – RVA_Lesion 
        0=RVA not involved,  1=RVA involved. 
BY – LVA Lesion 
         0=LVA not involved,  1=LVA involved. 
BZ -  RCCA lesion 
         0=RCCA not involved,  1=RCCA involved. 
CA -  LCCA lesion 
         0=LCCA not involved,  1=LCCA involved. 
CB -  RICA lesion 
         0=RICA not involved,  1=RICA involved. 
CC -  LICA lesion 
         0=LICA not involved,  1=LICA involved. 
CD -  Cor Art lesion 
         0=CA not involved,  1=CA involved. 
CE -  Pulm  Art lesion 
         0=PA not involved,  1=PA involved. 
CF -  Celiac  Art lesion 
          0=CA not involved,  1=CA involved. 
CG -  SMA lesion 
          0=SMA not involved,  1=SMA involved. 
CH - IMA lesion 
        0=IMA not involved,  1=IMA involved 
CI  -  RRA lesion 
         0=RRA not involved,  1=RRA involved 
CJ -   LRA lesion 
         0=LRA not involved,  1=LRA involved 
CK -  Bilat. RA lesion 
         0=Bilat RA not involved,  1=Bilat RA involved 
CL -   Iliac lesion 
        0=Iliac not involved,  1=Iliac involved 
CM - CFA lesion 
        0=CFA not involved,  1=CFA involved 
CN - SFA lesion 
        0=SFA not involved,  1=SFA involved 
CO – Clinical criteria C + 
         0= Cor. Artery not involved ,  1= Cor. Artery involved 
CP -  Clinical criteria P + 
         0= Pulm. Artery not involved ,  1= Pulm. Artery involved 
 
CQ -  Disease activity on first visit 
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          1=Active, 2=Smouldering, 3=Inactive. 
CR -  Disease activity on last follow-up visit 
          1=Active, 2=Smouldering, 3=Inactive. 
CS – Type of Takayasu arteritis 
          1/2/3/4/5. 
CT -  Response of medical treatment 
         1=Good, 2=Satisfactory, 3=Poor. 
CU -  Response of interventional  treatment 
         1=Good, 2=Satisfactory, 3=Poor. 
 
 
 
 
 
 
 
 
 
 
           
 
 
 
 
 
MASTER CHART
CaseNo Pt. Name Hosp. No. Age Sex M-1F-2 B.M.I Typeof T.A. Year of onset of symptom Symp_status C_Symp_None C.Symp_Fatigue
1 Pratyusa Mukherjee 544503C 56 2 24 2 1,985 1 0 1
2 Pakhi Haldar 070891F 17 2 16 3 2,010 1 0 1
3 Prince Tonk 534019D 22 1 17 5 2,010 1 0 0
4 Paramjeet Gupta 716317C 35 2 18 1 2,006 1 0 0
5 Rebecca Chalianmawii 965256D 25 2 27 1 2,010 1 0 1
6 Ridalin Gatphoh 129862B 36 2 22 5 1,997 1 0 1
7 Shivarajeshwari 972401D 26 2 20 1 2,011 1 1 0
8 Kumari Nag 752827c 24 2 26 5 2,005 1 0 1
9 Shashi Bala Sinha 598362D 63 2 35 5 2,009 1 0 1
10 Pinki Das Karmakar 309437D 29 2 27 5 2,008 1 1 0
11 Amit Kumar 176547D 26 1 19 2 2,007 1 0 1
12 Chitrakala 714166C 23 2 18 3 2,005 1 0 0
13 Nisha Marbaniang 090984F 36 2 25 5 2,011 1 0 1
14 Anamika Devi 078354F 34 2 28 5 2,003 1 0 1
15 Jesela Ali 071377F 32 2 26 1 2,005 1 1 0
16 Mohammed Kasim.M 095392F 37 1 27 5 2,011 1 0 0
17 Shalini Guha 019378F 15 2 27 5 2,010 1 0 1
18 Metali Goswami 948963D 32 2 19 1 2,003 1 0 1
19 Triptikana De 952223B 37 2 25 3 2,000 1 1 0
20 Bula Bose 324736D 37 2 33 4 1,990 1 0 1
21 Soma Mondal 070910F 29 2 27 4 2,000 1 0 1
22 Anna Rani Basak 072918F 20 2 17 5 2,010 1 0 1
23 Hridya Roy 876074D 14 1 21 4 2,009 1 0 1
24 Sikha Das 115596D 44 2 30 1 2,007 1 1 0
25 Swapna Samadar 668220C 50 2 17 5 1,998 1 0 0
26 Sonali Chakraborty 596696D 50 2 31 1 2,007 1 1 0
27 Anita 059454D 26 2 21 5 2,007 1 0 1
28 Kanika Jana 976278D 51 2 18 5 1,990 1 0 1
29 Faruk Molla 407093D 14 1 17 4 2,009 1 0 1
30 Janani G. 978164D 12 2 14 2 2,011 1 0 1
31 Chitra Maya Powdyel 269071D 19 2 19 5 2,008 1 0 1
32 Sadha Mary 700459B 41 2 25 1 2,001 1 0 1
33 Evangeline.L.Nongbri 823414D 29 2 21 5 2,008 1 0 1
34 Narayan Pandit 043509F 30 1 17 1 2,004 1 0 0
35 Strongwel Mawkhling 750888D 61 1 19 5 2,005 1 0 0
36 Tinku Ghosh 055039F 22 2 16 5 2,006 1 1 0
37 Sunil Kumar Shaw 832069D 23 1 23 5 2,010 1 1 0
38 Sangita Ghosh 772261D 24 2 25 5 2,010 1 0 1
39 Shikaka Paul 438799C 45 2 25 2 2,003 1 0 1
40 Poonam Lata 794982C 24 2 23 5 2,005 1 1 0
41 Macha Lavania 010116F 23 2 21 1 2,010 1 1 0
42 Dullu Haldar 000722F 38 2 21 5 1,990 0 1 0
MASTER CHART
CaseNo Pt. Name Hosp. No. Age Sex M-1F-2 B.M.I Typeof T.A. Year of onset of symptom Symp_status C_Symp_None C.Symp_Fatigue
43 Mafuz Begum 041930F 38 2 27 5 2,008 1 0 1
44 Praveen Kumar 959878D 29 1 26 1 2,008 1 1 0
45 Parinita Porel 931349B 24 2 17 4 1,998 1 0 1
46 Sarveriyar K 938279D 21 1 21 5 2,009 1 1 0
47 Sushil Kumar 611978D 47 1 23 5 2,006 1 1 0
48 Chandrakala R. 004090F 25 2 28 5 2,010 1 1 0
49 Saraswati Gorai 953058d 33 2 20 1 2,009 1 0 1
50 Sova Bardhan 005098F 53 2 23 1 2,007 1 0 0
51 Juli Laskar 995329D 16 2 18 3 2,010 1 0 1
52 Bijon Mondal 023705F 45 1 22 5 2,006 1 0 0
53 Geetha R. 809433D 30 2 23 1 2,009 1 0 1
54 Saba Naz 606088D 12 2 16 5 2,009 1 1 0
55 Amina Bibi 006972F 21 2 22 3 2,009 1 0 1
56 Ashok kumar Pramanik 789627D 47 1 19 5 2,005 1 0 0
57 Santi Majumder 782923D 59 1 21 3 2,007 1 0 1
58 Sagar Chandra Mondal 862417D 42 1 24 4 2,008 0 1 0
59 Sivarajeswari 972401D 26 2 18 1 2,011 1 1 0
60 Kalaivani K. 718214D 39 2 33 1 2,009 1 1 0
61 Kusum lata Prasad 366269D 64 2 27 5 2,002 1 0 1
62 Sherab choden 720845D 24 1 18 4 2,009 1 0 0
63 Sheli Benerjee 958128D 37 2 22 5 2,002 1 0 1
64 Arpita Ash 760627D 16 2 15 5 2,005 1 0 1
65 Nipa Brahama 885661d 25 2 23 5 2,010 1 1 0
66 Nita Devi 931317D 21 2 22 5 2,009 1 0 1
67 Naga Bhagyasree N 854108D 21 2 18 5 2,009 1 1 0
68 Lynda Pertin 056879D 20 2 24 2 2,007 1 1 0
69 Baby Sarkar 693809c 40 2 23 3 2,005 1 0 0
70 Lekhi Choten 927204D 20 2 18 5 2,007 1 0 1
71 Kaveri Sundarajan 966143D 27 2 18 3 2,008 1 1 0
72 Mutharacha Gopi 731577C 45 2 22 5 2,002 1 1 0
73 Subaja R. 747763D 26 2 41 2 2,009 1 0 1
74 Rupchand Mondal 668159C 35 1 18 5 2,006 1 0 0
75 Molina Dey 996793D 44 2 25 1 2,001 1 0 1
76 Parabati Sah 081549D 39 2 26 1 2,007 1 0 1
77 Mutharacha Gopi 731577C 46 2 22 5 2,005 1 1 0
78 Ratna Diwan 813365C 42 2 26 1 2,006 1 0 1
79 Leki Chotten 927204D 21 2 18 5 2,008 1 0 1
80 Sanjay Lhamo 926356D 16 2 20 3 2,009 1 0 1
81 Revathy M. 200259D 25 2 28 4 2,011 1 1 0
82 Rama Jaiswal 507404C 29 2 22 3 2,002 1 0 1
83 Suganthi K 109356C 45 1 15 4 2,012 1 1 0
84 Jeevanandam A 236812D 40 2 20 1 1,999 1 1 0
MASTER CHART
CaseNo Pt. Name Hosp. No. Age Sex M-1F-2 B.M.I Typeof T.A. Year of onset of symptom Symp_status C_Symp_None C.Symp_Fatigue
85 Ranjit Saha 121901F 47 1 15 3 2,012 1 1 0
86 Pushparani E 062763F 30 2 23 1 2,010 1 0 0
87 Lalita Danapat 129260B 45 2 24 3 1,992 1 1 0
88 Dr malooqa 141597F 38 2 31 1 2,006 1 0 0
89 Pratima Khamaru 135293D 47 2 30 5 2,006 1 0 1
90 Dr. N S Thakur 058928F 46 1 26 1 2,005 1 1 0
91 Santa Biswas 100314F 31 2 21 1 2,009 1 0 1
92 Chandra Sivakumari 138770F 22 2 22 5 2,009 1 0 1
93 Valentina D 862061D 46 2 20 5 2,002 1 0 1
94 Suganya M. 232578F 23 2 21 1 2,010 1 0 1
95 Hyfa B.V. 728891D 21 2 19 5 2,009 1 0 1
96 Soma Bhowmik 498876B 39 2 23 2 1,996 1 0 1
97 Sangeeta Srivastava 139842F 42 2 29 1 2,009 1 0 1
98 Manti Deb 905341D 27 2 23 4 2,007 1 1 0
99 Babli Kumari 217349F 15 2 5 2,011 1 1 0
100 Jagtapati Dutta 884494C 56 1 26 5 2,003 1 1 0
101 Vasanta T. 615525D 34 2 30 5 2,004 1 0 1
102 Santosh Kumar 930583C 19 1 17 2 2,005 1 0 1
103 Mohammed Mubarak M. 162096F 7 1 1 2,011 1 0 0
104 Jainab Asif 175625F 22 2 5 2,010 1 0 0
105 Sharmishtha Roy 192149F 18 2 18 2 2,009 1 0 0
106 Naga Bhavani 176430D 13 2 27 3 2,007 1 0 1
107 Rama Devi R. 147104F 38 2 29 1 1,998 1 0 1
108 Nayan Dey 115862C 27 1 16 5 2,001 1 0 1
109 Eswaran M B 021211F 42 1 27 5 2,009 1 1 0
110 Kum Kum Kumari 168800F 24 2 16 5 2,007 1 1 0
111 Vishal Wahlong 227304F 42 1 28 1 2,012 1 0 1
112 HafeezAhemed 229218F 10 1 16 5 2,011 1 1 0
113 Sajana Philip 244712F 33 2 21 3 2,012 1 1 0
114 Saroj Srivastava 293967F 36 2 30 1 2,009 1 0 1
115 Sixty pyrangap 297075F 30 2 22 1 2,008 1 0 1
116 Chaya Kiran 538698C 19 2 24 5 2,005 1 0 1
117 Sandhya Manda 700646D 31 2 24 1 2,008 1 0 0
118 Maya Prasad 157399F 48 2 28 5 2,011 1 0 1
119 Parvathi K 356449F 30 2 25 4 2,012 1 1 0
120 Anima Olive Khalko 356435F 20 2 19 5 2,012 1 0 1
121 Muni Rika Chmomin 042918f 32 2 20 1 2,011 1 1 0
122 Rama Das Gupta 069847C 32 2 25 5 2,001 1 1 0
123 Kavitha A 106232F 31 2 25 1 2,011 1 1 0
124 Sarita Devi 151458F 31 2 25 1 2,008 1 0 0
125 Sidharth Shah 020873F 31 1 24 3 2,010 1 0 0
MASTER CHART
CaseNo C.Symp_Fever C.Symp_Wt.Loss C.Symp_Myalgia C.Symp_Arthralgia H.RelatedSymp_none H.Related_E Dysnoea H.Relatd_PND
1 0 0 0 1 0 1 0
2 0 1 0 0 0 1 0
3 0 0 0 0 0 1 0
4 0 1 0 0 1 0 0
5 0 0 1 0 0 1 0
6 0 1 1 0 1 0 0
7 0 0 0 0 0 1 0
8 0 0 0 0 0 1 0
9 0 0 1 0 0 1 0
10 0 0 0 0 1 0 0
11 1 1 0 0 1 0 0
12 1 0 1 1 0 1 0
13 0 0 1 0 0 1 0
14 1 0 0 0 0 1 1
15 0 0 0 0 1 0 0
16 0 0 1 0 1 0 0
17 1 1 1 0 0 0 0
18 0 0 0 0 1 0 0
19 0 0 0 0 1 0 0
20 0 0 0 0 0 1 0
21 0 0 0 0 0 1 0
22 0 0 0 0 0 1 0
23 0 0 0 0 1 0 0
24 0 0 0 0 0 1 0
25 0 1 0 1 0 1 0
26 0 0 0 0 0 1 0
27 1 1 1 0 0 1 0
28 0 1 0 0 1 0 0
29 0 0 0 0 1 0 0
30 0 0 0 0 0 1 0
31 1 1 1 0 0 1 0
32 0 1 1 1 0 1 0
33 0 0 0 0 0 0 0
34 0 1 0 0 1 0 0
35 0 1 0 0 1 0 0
36 0 0 0 0 0 1 0
37 0 0 0 0 0 1 0
38 1 1 0 0 1 0 0
39 0 0 1 1 0 1 0
40 0 0 0 0 1 0 0
41 0 0 0 0 1 0 0
42 0 0 0 0 1 0 0
MASTER CHART
CaseNo C.Symp_Fever C.Symp_Wt.Loss C.Symp_Myalgia C.Symp_Arthralgia H.RelatedSymp_none H.Related_E Dysnoea H.Relatd_PND
43 0 0 0 1 0 1 0
44 0 0 0 0 1 0 0
45 1 0 1 1 0 1 1
46 0 0 0 0 1 0 0
47 0 0 0 0 0 1 0
48 0 0 0 0 1 0 0
49 0 0 0 1 0 1 0
50 0 1 0 0 0 0 0
51 0 1 0 0 1 0 0
52 0 1 0 0 0 1 0
53 0 0 1 0 0 1 0
54 0 0 0 0 0 1 0
55 0 0 0 0 0 1 0
56 0 0 1 0 0 0 0
57 0 0 0 0 0 1 0
58 0 0 0 0 1 0 0
59 0 0 0 0 0 1 0
60 0 0 0 0 0 1 1
61 0 1 0 0 0 0 0
62 0 0 0 0 1 0 0
63 0 0 1 1 1 0 0
64 0 0 0 0 1 0 0
65 0 0 0 0 1 0 0
66 0 0 0 0 0 0 0
67 0 0 0 0 0 0 0
68 0 0 0 0 1 0 0
69 0 0 0 1 1 0 0
70 0 0 0 0 0 1 0
71 0 0 0 0 1 0 0
72 0 0 0 0 1 0 0
73 0 0 0 0 0 1 0
74 0 1 0 0 1 0 0
75 0 0 1 0 0 1 0
76 0 0 0 0 0 1 0
77 0 0 0 0 1 0 0
78 0 0 1 0 1 0 0
79 0 0 0 0 0 1 0
80 1 1 0 0 0 1 0
81 0 0 0 0 1 0 0
82 0 0 0 1 0 1 0
83 0 0 0 0 0 1 0
84 0 0 0 0 1 0 0
MASTER CHART
CaseNo C.Symp_Fever C.Symp_Wt.Loss C.Symp_Myalgia C.Symp_Arthralgia H.RelatedSymp_none H.Related_E Dysnoea H.Relatd_PND
85 0 0 0 0 0 1 0
86 0 0 0 1 0 1 0
87 0 0 0 0 1 0 0
88 0 0 1 0 0 0 0
89 0 0 0 0 1 0 0
90 0 0 0 0 1 0 0
91 0 0 0 0 1 0 0
92 1 0 0 1 1 0 0
93 1 0 0 0 0 1 0
94 0 0 0 1 1 0 0
95 0 0 0 0 1 0 0
96 0 0 0 0 0 1 0
97 0 0 0 0 1 0 0
98 0 0 0 0 1 0 0
99 0 0 0 0 1 0 0
100 0 0 0 0 0 0 0
101 0 0 0 1 1 0 0
102 0 1 0 0 1 0 0
103 1 1 0 0 0 1 0
104 1 1 0 0 1 1 0
105 1 0 1 0 0 1 0
106 1 0 0 0 0 1 0
107 0 0 1 0 1 0 0
108 0 1 0 0 1 0 0
109 0 0 0 0 1 1 0
110 0 0 0 0 0 1 0
111 0 0 0 0 1 0 0
112 0 0 0 0 1 0 0
113 0 0 0 0 1 0 0
114 0 0 1 0 1 0 0
115 0 0 0 1 1 0 0
116 0 0 0 1 0 1 0
117 0 0 1 1 1 0 0
118 0 0 1 0 0 1 0
119 0 0 0 0 0 1 0
120 1 0 0 0 0 1 0
121 0 0 0 0 1 0 0
122 0 0 0 0 1 0 0
123 0 0 0 0 1 0 0
124 0 0 0 1 1 0 0
125 1 0 0 0 1 0 0
MASTER CHART
CaseNo H.Related_Orthopnea H.Reltemad_Pedal edema H.Related_Angina H.Related_Palpitation Neurological_None Neurological_Giddiness
1 0 0 0 0 0 1
2 0 0 0 1 1 0
3 0 0 0 0 1 0
4 0 0 0 0 0 1
5 0 1 0 0 0 0
6 0 0 0 0 0 1
7 0 0 1 0 0 1
8 0 0 0 0 0 0
9 0 1 0 0 0 0
10 0 0 0 0 0 1
11 0 0 0 0 1 0
12 0 0 0 0 0 1
13 0 0 0 0 0 1
14 0 1 0 0 1 0
15 0 0 0 0 1 0
16 0 0 0 0 1 0
17 0 0 0 1 1 0
18 0 0 0 0 0 1
19 0 0 0 0 0 0
20 0 0 0 0 0 0
21 0 0 0 0 0 0
22 0 0 0 0 0 1
23 0 0 0 0 0 1
24 0 0 0 0 0 1
25 0 0 1 0 0 0
26 0 0 1 0 0 0
27 0 1 0 0 0 1
28 0 0 0 0 0 0
29 0 0 0 0 0 0
30 0 0 0 0 1 0
31 0 0 1 1 0 1
32 1 0 1 1 0 1
33 0 0 0 1 0 1
34 0 0 0 0 1 0
35 0 0 0 0 0 1
36 0 0 1 1 1 0
37 0 0 0 0 1 0
38 0 0 0 0 0 1
39 0 0 1 0 1 0
40 0 0 0 0 0 0
41 0 0 0 0 0 1
42 0 0 0 0 0 0
MASTER CHART
CaseNo H.Related_Orthopnea H.Reltemad_Pedal edema H.Related_Angina H.Related_Palpitation Neurological_None Neurological_Giddiness
43 0 0 1 0 0 1
44 0 0 0 0 0 0
45 1 0 0 0 1 0
46 0 0 0 0 0 0
47 0 0 0 0 0 0
48 0 0 0 0 1 0
49 0 1 0 0 0 1
50 0 1 0 0 1 0
51 0 0 0 0 0 1
52 1 0 0 1 0 1
53 0 0 0 0 0 1
54 0 0 0 0 0 0
55 0 0 0 0 0 1
56 0 0 0 1 0 1
57 0 0 0 0 1 0
58 0 0 0 0 1 0
59 0 0 1 1 0 0
60 0 1 0 0 0 0
61 0 0 0 1 0 1
62 0 0 0 0 1 0
63 0 0 0 0 1 0
64 0 0 0 0 1 0
65 0 0 0 0 1 0
66 0 0 0 1 1 0
67 0 0 0 1 1 0
68 0 0 0 0 1 0
69 0 0 0 0 1 0
70 0 0 0 1 1 0
71 0 0 0 0 0 1
72 0 0 0 0 0 0
73 0 0 0 0 0 1
74 0 0 0 0 0 1
75 0 1 0 0 0 1
76 0 0 0 1 0 1
77 0 0 0 0 0 0
78 0 0 0 0 0 1
79 0 0 0 1 1 0
80 0 0 0 1 0 1
81 0 0 0 0 1 0
82 0 0 0 1 0 1
83 0 0 0 0 1 0
84 0 0 0 0 1 0
MASTER CHART
CaseNo H.Related_Orthopnea H.Reltemad_Pedal edema H.Related_Angina H.Related_Palpitation Neurological_None Neurological_Giddiness
85 0 0 0 0 1 0
86 0 0 0 1 1 0
87 0 0 0 0 0 0
88 0 0 0 0 1 0
89 0 0 0 0 0 0
90 0 0 0 0 0 1
91 0 0 0 0 0 0
92 0 0 0 0 1 0
93 0 0 1 1 0 1
94 0 0 0 1 1 1
95 0 0 0 0 0 0
96 0 0 0 1 1 0
97 0 0 0 0 1 0
98 0 0 0 0 1 0
99 0 0 0 0 0 1
100 0 0 1 1 0 0
101 0 0 0 0 1 0
102 0 0 0 0 1 0
103 0 0 0 0 1 0
104 0 0 0 0 0 0
105 0 0 1 0 0 1
106 1 0 0 0 1 0
107 0 0 0 0 1 0
108 0 0 0 0 0 1
109 0 0 0 0 1 0
110 0 0 0 0 0 0
111 0 0 0 0 1 0
112 0 0 0 0 0 0
113 0 0 0 0 0 1
114 0 0 0 0 0 0
115 0 0 0 0 0 1
116 1 0 0 0 1 0
117 0 0 0 0 1 0
118 0 0 1 0 0 1
119 0 0 0 0 1 0
120 0 0 0 0 1 0
121 0 0 0 0 1 0
122 0 0 0 0 1 0
123 0 0 0 0 0 0
124 0 0 0 0 1 0
125 0 0 0 0 1 0
MASTER CHART
CaseNo Neurological_Syncope Neurological_TIA Neurological_Stroke Neurological_Blurredvision Neurological_Neckpain Neurological_Seizure
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 1 0 1 0 0 0
5 0 0 0 0 1 0
6 0 0 0 1 1 0
7 0 0 1 1 0 0
8 0 0 0 1 0 0
9 1 0 0 0 0 0
10 1 0 0 0 0 0
11 0 0 0 0 0 0
12 0 0 0 0 1 0
13 1 0 1 1 0 0
14 0 0 0 0 0 0
15 0 0 0 0 0 0
16 0 0 0 0 0 0
17 0 0 0 0 0 0
18 1 0 0 1 0 0
19 0 0 0 1 0 0
20 0 0 0 0 1 0
21 0 0 0 1 0 0
22 0 0 0 0 0 0
23 0 0 0 0 0 0
24 0 0 0 0 0 0
25 1 0 0 1 1 0
26 1 0 0 1 0 0
27 1 0 0 0 0 1
28 0 0 0 0 0 1
29 1 0 0 1 0 1
30 0 0 0 0 0 0
31 0 0 0 0 1 0
32 1 0 0 0 0 0
33 1 0 0 0 0 0
34 0 0 0 0 0 0
35 0 0 0 1 0 0
36 0 0 0 0 0 0
37 0 0 0 0 0 0
38 0 0 0 0 1 0
39 0 0 0 0 0 0
40 0 0 0 0 1 0
41 1 0 0 0 0 0
42 0 0 1 0 0 0
MASTER CHART
CaseNo Neurological_Syncope Neurological_TIA Neurological_Stroke Neurological_Blurredvision Neurological_Neckpain Neurological_Seizure
43 0 0 0 1 0 0
44 0 0 1 1 1 0
45 0 0 0 0 0 0
46 0 0 0 0 1 0
47 0 0 1 0 0 0
48 0 0 0 0 0 0
49 1 0 0 0 0 0
50 0 0 0 0 0 0
51 0 0 0 1 0 0
52 0 0 1 0 0 0
53 0 0 0 0 0 0
54 0 1 0 0 0 0
55 0 0 0 0 0 0
56 0 0 0 1 0 0
57 0 0 0 0 0 0
58 0 0 0 0 0 0
59 0 0 1 0 1 0
60 0 0 1 0 0 1
61 1 0 0 1 1 0
62 0 0 0 0 0 0
63 0 0 0 0 0 0
64 0 0 0 0 0 0
65 0 0 0 0 0 0
66 0 0 0 0 0 0
67 0 0 1 0 0 0
68 0 0 0 0 0 0
69 0 0 0 0 0 0
70 0 0 0 0 0 0
71 0 0 0 1 0 0
72 0 0 0 0 1 0
73 0 0 0 0 0 0
74 1 0 0 0 0 0
75 1 0 0 0 0 0
76 0 0 0 1 1 0
77 0 0 0 0 1 1
78 1 0 0 0 1 0
79 0 0 0 0 0 0
80 1 0 0 0 0 0
81 0 0 0 0 0 0
82 0 0 0 0 0 0
83 0 0 0 0 0 0
84 0 0 0 0 0 0
MASTER CHART
CaseNo Neurological_Syncope Neurological_TIA Neurological_Stroke Neurological_Blurredvision Neurological_Neckpain Neurological_Seizure
85 0 0 0 0 0 0
86 0 0 0 0 0 0
87 0 0 0 1 0 0
88 0 0 0 0 0 0
89 0 0 0 0 1 0
90 0 0 0 1 0 0
91 0 0 1 1 0 0
92 0 0 0 0 0 0
93 0 0 0 0 0 0
94 1 0 0 0 0 0
95 1 1 0 1 1 0
96 0 0 0 0 0 0
97 0 0 0 0 0 0
98 0 0 0 0 0 0
99 1 0 1 1 0 1
100 1 0 0 0 0 0
101 0 0 0 0 0 0
102 0 0 0 0 0 0
103 0 0 0 0 0 0
104 0 0 1 0 1 0
105 0 0 0 0 0 0
106 0 0 0 0 0 0
107 0 0 0 0 0 0
108 0 0 0 0 0 0
109 0 0 0 0 0 0
110 0 0 1 0 0 0
111 0 0 0 0 0 0
112 0 0 0 0 0 1
113 0 0 0 0 0 0
114 1 0 0 1 0 0
115 1 1 1 1 1 1
116 0 0 0 0 0 0
117 0 0 0 0 0 0
118 1 0 0 1 0 0
119 0 0 0 0 0 0
120 0 0 0 0 0 0
121 0 0 0 0 0 0
122 0 0 0 0 0 0
123 0 0 1 0 0 0
124 0 0 0 0 0 0
125 0 0 0 0 0 0
MASTER CHART
CaseNo Mesenteric_Post Abd pain Mesenteric_Anorexia Mesenteric_Wtloss Renal_None Renal_HTN Renal_Renalfailure U.L._None U.L._RULF
1 0 1 0 0 1 0 0 0
2 0 0 1 0 1 0 0 0
3 0 0 0 0 1 0 0 1
4 0 1 1 1 0 0 1 0
5 1 0 0 1 0 0 0 0
6 0 0 0 1 0 0 0 0
7 0 0 0 1 0 0 0 0
8 0 0 0 0 1 0 0 0
9 0 0 0 1 0 0 0 0
10 0 0 0 0 1 0 0 0
11 0 0 0 0 1 0 0 0
12 0 0 0 0 1 0 1 0
13 0 0 0 1 0 0 0 0
14 0 0 0 1 0 0 0 0
15 0 0 0 1 0 0 0 0
16 1 0 0 1 0 0 1 0
17 0 1 1 1 0 0 0 1
18 0 1 0 1 0 0 0 0
19 0 0 0 0 1 0 1 0
20 0 0 0 0 1 0 0 0
21 0 0 0 0 1 0 1 0
22 0 0 0 0 1 0 0 0
23 0 0 0 0 1 0 1 0
24 0 0 0 0 1 0 1 0
25 1 0 1 1 0 0 0 0
26 0 0 0 1 0 0 0 0
27 0 0 1 1 0 0 0 0
28 0 0 1 1 0 0 1 0
29 0 0 0 0 1 0 1 0
30 0 0 0 0 1 1 1 0
31 0 0 0 1 0 0 0 1
32 0 1 1 1 0 0 0 1
33 0 0 0 0 1 0 0 1
34 0 0 0 1 0 0 0 1
35 0 1 1 0 1 0 1 0
36 0 0 0 0 1 0 1 0
37 0 0 0 0 1 0 0 0
38 0 0 0 1 0 0 0 0
39 0 0 0 0 1 0 1 0
40 0 0 0 0 1 0 0 0
41 0 0 0 0 1 0 1 0
42 0 0 0 0 1 0 1 0
MASTER CHART
CaseNo Mesenteric_Post Abd pain Mesenteric_Anorexia Mesenteric_Wtloss Renal_None Renal_HTN Renal_Renalfailure U.L._None U.L._RULF
43 0 0 0 1 0 0 0 1
44 0 0 0 1 0 0 1 0
45 0 1 0 0 1 0 1 0
46 0 0 0 0 0 0 1 0
47 0 0 0 0 1 0 1 0
48 0 0 0 0 1 0 1 0
49 0 0 0 1 0 0 0 0
50 0 0 0 0 1 0 0 1
51 1 1 0 0 1 0 1 0
52 0 1 0 1 0 0 0 0
53 0 0 0 1 0 0 0 1
54 1 0 0 1 0 0 0 0
55 0 0 0 0 1 0 1 0
56 0 0 0 0 1 0 0 1
57 0 0 0 0 1 0 1 0
58 0 0 0 0 1 0 1 0
59 0 0 0 0 1 0 0 0
60 0 0 0 0 1 0 0 0
61 1 0 0 0 1 0 0 0
62 0 0 0 0 1 0 1 0
63 0 0 0 0 1 0 1 0
64 0 0 0 0 1 0 0 0
65 0 0 0 0 1 0 1 0
66 0 0 0 0 1 0 0 0
67 0 0 0 0 1 0 1 0
68 0 0 0 0 1 0 1 0
69 0 0 0 0 1 0 1 0
70 0 0 0 0 1 0 1 0
71 0 0 0 0 1 0 1 0
72 0 0 0 0 1 0 0 0
73 0 0 0 0 1 0 0 0
74 0 0 1 0 1 1 0 0
75 0 0 0 0 1 0 0 0
76 0 0 0 0 0 0 0 0
77 0 0 0 0 1 0 0 0
78 0 0 0 1 0 0 1 0
79 0 0 0 0 1 0 1 0
80 0 0 1 1 0 0 0 0
81 0 0 0 0 1 0 1 0
82 1 0 0 0 1 0 0 0
83 0 0 0 0 1 0 1 0
84 0 0 0 0 1 0 0 1
MASTER CHART
CaseNo Mesenteric_Post Abd pain Mesenteric_Anorexia Mesenteric_Wtloss Renal_None Renal_HTN Renal_Renalfailure U.L._None U.L._RULF
85 0 0 0 0 1 0 1 0
86 0 0 0 0 0 0 0 0
87 0 0 0 0 1 0 0 1
88 0 0 0 1 0 0 0 0
89 0 0 0 0 1 0 0 0
90 0 0 0 1 0 0 0 0
91 0 0 0 0 1 0 1 0
92 0 0 0 1 0 0 0 0
93 1 0 0 1 0 0 0 0
94 0 0 0 1 0 0 0 0
95 0 0 0 1 0 0 0 1
96 0 0 0 0 1 0 0 0
97 0 0 0 0 0 0 0 0
98 0 0 0 0 1 0 1 0
99 0 0 0 0 1 0 1 0
100 1 0 0 1 1 0 1 0
101 0 0 0 0 1 0 0 0
102 0 0 0 0 0 1 1 0
103 0 0 0 0 0 0 1 0
104 0 0 0 0 1 0 0 0
105 0 0 0 1 0 0 1 0
106 0 0 0 0 1 0 1 0
107 0 0 0 1 0 0 0 0
108 0 0 0 1 0 0 1 0
109 0 0 0 0 1 0 0 0
110 0 0 0 0 1 0 0 0
111 0 0 0 1 0 0 0 0
112 0 0 0 0 1 0 1 0
113 0 0 0 0 1 0 1 0
114 0 0 0 1 0 0 0 0
115 0 0 0 1 0 0 0 1
116 0 0 0 1 1 0 1 0
117 0 0 0 1 0 0 0 0
118 1 1 0 0 0 0 0 0
119 0 0 0 0 1 0 1 0
120 0 0 0 0 1 0 1 0
121 0 0 0 1 0 0 0 1
122 0 0 0 0 1 0 0 1
123 0 0 0 1 0 0 1 0
124 0 0 0 1 0 0 0 0
125 0 0 0 1 1 0 1 0
MASTER CHART
CaseNo U.L._RULC CaseNo U.L._LULF U.L._LULC UL_BULF U.L._BULC L.L._None L.L._RLLF LL_RLLC LL_LLLF LL_LLLC LL_BLLF LL_BLLC
1 0 1 0 0 1 1 1 0 0 0 0 0 0
2 0 2 0 0 1 1 1 0 0 0 0 0 0
3 1 3 0 0 0 0 0 1 1 0 0 0 0
4 0 4 0 0 0 0 1 0 0 0 0 0 0
5 0 5 1 1 0 0 1 0 0 0 0 0 0
6 0 6 0 0 1 1 1 0 0 0 0 0 0
7 0 7 1 1 0 0 1 0 0 0 0 0 0
8 0 8 1 1 0 0 0 0 0 0 0 1 1
9 0 9 0 0 1 1 1 0 0 0 0 0 0
10 0 10 1 1 0 0 1 0 0 0 0 0 0
11 0 11 1 1 0 0 0 0 0 0 0 0 0
12 0 12 0 0 0 0 0 0 0 0 0 1 1
13 0 13 1 1 0 0 1 0 0 0 0 0 0
14 0 14 1 1 0 0 1 0 0 0 0 0 0
15 0 15 0 0 1 1 1 0 0 0 0 0 0
16 0 16 0 0 0 0 0 0 0 0 1 1 1
17 1 17 0 0 0 0 1 0 0 0 0 0 0
18 0 18 0 0 1 0 0 1 0 0 0 0 0
19 0 19 0 0 0 0 1 0 0 0 0 0 0
20 0 20 0 0 0 1 0 0 0 0 0 1 1
21 0 21 0 0 0 0 1 0 0 0 0 0 0
22 0 22 1 1 0 0 0 0 0 0 0 1 1
23 0 23 0 0 0 0 0 0 0 0 0 0 1
24 0 24 0 0 0 0 0 0 0 0 0 1 1
25 0 25 0 0 1 1 1 0 0 0 0 0 0
26 0 26 1 1 0 0 0 0 0 1 1 0 0
27 0 27 0 0 1 1 1 0 0 0 0 0 0
28 0 28 0 0 0 0 1 0 0 0 0 0 0
29 0 29 0 0 0 0 1 0 0 0 0 0 0
30 0 30 0 0 0 0 0 1 1 1 1 0 0
31 1 31 0 0 0 0 0 0 0 0 0 1 1
32 1 32 1 1 0 0 0 0 0 1 1 0 0
33 1 33 0 0 0 0 1 0 0 0 0 0 0
34 1 34 0 0 0 0 1 0 0 0 0 0 0
35 0 35 0 0 0 0 1 0 0 0 0 0 0
36 0 36 0 0 0 0 0 0 0 0 0 1 1
37 0 37 1 1 0 0 1 0 0 0 0 0 0
38 0 38 0 0 1 1 1 0 0 0 0 0 0
39 0 39 0 0 0 0 0 0 0 0 0 1 1
40 0 40 1 1 0 0 0 0 0 1 1 0 0
41 0 41 0 0 0 0 1 0 0 0 0 0 0
42 0 42 0 0 0 0 1 0 0 0 0 0 0
MASTER CHART
CaseNo U.L._RULC CaseNo U.L._LULF U.L._LULC UL_BULF U.L._BULC L.L._None L.L._RLLF LL_RLLC LL_LLLF LL_LLLC LL_BLLF LL_BLLC
43 1 43 0 0 0 0 0 1 1 0 0 0 0
44 0 44 0 0 0 0 1 0 0 0 0 0 0
45 0 45 0 0 0 0 0 0 0 0 0 1 1
46 0 46 0 0 0 0 1 0 0 0 0 0 0
47 0 47 0 0 0 0 0 0 0 0 0 1 1
48 0 48 0 0 0 0 1 0 0 0 0 0 0
49 0 49 0 1 0 0 0 0 0 0 0 0 1
50 1 50 0 0 0 0 0 0 0 0 0 1 1
51 0 51 0 0 0 0 0 0 1 0 0 0 0
52 0 52 0 0 1 0 0 0 0 0 0 1 1
53 1 53 0 0 0 0 1 0 0 0 0 0 0
54 0 54 0 0 1 0 1 0 0 0 0 0 0
55 0 55 0 0 0 0 1 0 0 0 0 0 0
56 1 56 0 0 0 0 0 0 0 0 0 1 1
57 0 57 0 0 0 0 0 0 0 0 0 0 0
58 0 58 0 0 0 0 1 0 0 0 0 0 0
59 0 59 1 1 0 0 1 0 0 0 0 0 0
60 0 60 0 0 1 1 1 0 0 0 0 0 0
61 0 61 1 1 0 0 1 0 0 0 0 0 0
62 0 62 0 0 0 0 1 0 0 0 0 0 0
63 0 63 0 0 0 0 0 0 0 0 0 1 1
64 0 64 0 0 0 1 0 0 0 0 0 0 1
65 0 65 0 0 0 0 1 0 0 0 0 0 0
66 0 66 1 1 0 0 1 0 0 0 0 0 0
67 0 67 0 0 0 0 0 0 0 0 0 1 1
68 0 68 0 0 0 0 1 0 0 0 0 0 0
69 0 69 0 0 0 0 1 0 0 0 0 0 0
70 0 70 0 0 0 0 0 1 1 1 1 0 0
71 0 71 0 0 0 0 1 0 0 0 0 0 0
72 0 72 1 1 0 0 1 0 0 0 0 0 0
73 0 73 1 1 0 0 0 0 0 0 0 1 1
74 0 74 0 0 0 0 1 0 0 0 0 0 0
75 1 75 0 1 0 0 1 0 0 0 0 0 0
76 0 76 0 0 1 1 1 1 1 1 1 1 1
77 0 77 1 1 0 0 1 0 0 0 0 0 0
78 0 78 0 0 0 0 1 0 0 0 0 0 0
79 0 79 0 0 0 0 0 0 0 0 0 1 1
80 0 80 0 0 1 1 0 0 0 0 0 1 1
81 0 81 0 0 0 0 1 0 0 0 0 0 0
82 0 82 1 1 0 0 0 0 0 0 0 1 1
83 0 83 0 0 0 0 1 0 0 0 0 0 0
84 1 84 0 0 0 0 1 0 0 0 0 0 0
MASTER CHART
CaseNo U.L._RULC CaseNo U.L._LULF U.L._LULC UL_BULF U.L._BULC L.L._None L.L._RLLF LL_RLLC LL_LLLF LL_LLLC LL_BLLF LL_BLLC
85 0 85 0 0 0 0 1 0 0 0 0 0 0
86 0 86 0 0 1 1 1 0 0 0 0 0 0
87 1 87 0 0 0 0 1 0 0 0 0 0 0
88 1 88 0 1 0 1 1 0 0 0 0 0 0
89 1 89 0 1 0 0 1 0 0 0 0 0 0
90 0 90 0 0 1 1 1 0 0 0 0 0 0
91 0 91 0 0 0 0 1 0 0 0 0 0 0
92 0 92 0 0 1 1 0 0 0 0 0 0 0
93 0 93 0 0 1 1 0 0 0 0 0 1 1
94 0 94 0 0 0 0 0 0 0 0 0 1 1
95 1 95 0 0 0 0 0 0 0 0 0 0 0
96 0 96 0 0 1 1 0 0 0 0 0 1 1
97 0 97 1 1 0 0 1 0 0 0 0 0 0
98 0 98 0 0 0 0 1 0 0 0 0 0 0
99 0 99 0 0 0 0 1 0 0 0 0 0 0
100 0 100 0 0 0 0 0 0 1 0 0 0 0
101 0 101 0 0 1 1 1 0 0 0 0 0 0
102 0 102 0 0 0 0 0 0 0 0 0 1 1
103 0 103 0 0 0 0 0 0 0 0 0 0 0
104 0 104 0 0 1 1 1 0 0 0 0 0 0
105 0 105 0 0 1 1 1 0 0 0 0 0 0
106 0 106 0 0 0 0 1 0 0 0 0 0 0
107 0 107 0 0 1 1 0 0 0 1 0 1 1
108 0 108 1 1 0 0 1 0 0 0 0 1 1
109 0 109 0 1 0 0 1 0 0 0 0 0 0
110 0 110 0 0 1 1 1 0 0 0 0 0 0
111 0 111 1 1 0 0 1 0 0 0 0 0 0
112 0 112 0 0 0 0 1 0 0 0 0 0 0
113 0 113 0 0 0 0 1 0 0 0 0 0 0
114 0 114 0 0 1 1 1 0 0 0 0 0 0
115 1 115 0 0 0 0 0 0 0 0 0 1 1
116 0 116 0 0 0 0 1 0 0 0 0 0 0
117 0 117 0 0 1 1 1 0 0 0 0 0 0
118 1 118 1 0 0 0 1 0 0 0 0 0 0
119 0 119 0 0 0 0 0 0 0 0 0 1 1
120 0 120 0 0 0 0 1 0 0 0 0 0 0
121 1 121 0 0 0 0 1 0 0 0 0 0 1
122 1 122 0 0 0 0 1 0 0 0 0 0 0
123 0 123 0 0 0 0 1 0 0 0 0 0 0
124 0 124 0 0 1 1 1 0 0 0 0 0 0
125 0 125 0 0 0 0 1 0 0 0 0 0 0
MASTER CHART
CaseNo Misc_Headache Misc_Abortion Misc_TB Misc_Epist Diag_MajorCr Diag._MinorCr ClinicalCr.Met ACRCr.Met TotalScore ITASScore ESR
1 1 0 0 0 0 3 1 1 5 11 36
2 1 0 0 0 2 3 1 1 5 15 12
3 0 0 0 0 1 3 1 1 4 8 5
4 1 1 1 1 2 2 1 1 4 9 90
5 0 0 0 0 2 2 1 1 5 9 80
6 1 1 1 1 2 2 1 1 5 10 13
7 1 1 0 0 2 3 1 1 4 13 80
8 1 0 0 0 0 2 1 1 5 10 15
9 0 0 0 0 2 3 1 1 4 5 51
10 1 0 0 0 2 4 1 1 4 5 28
11 0 0 0 0 2 2 1 1 4 4 97
12 1 0 0 0 1 2 1 0 2 4 16
13 0 0 1 0 2 3 1 1 6 11 21
14 0 1 0 0 2 4 1 1 5 13 50
15 0 0 0 0 2 2 1 1 5 5 45
16 0 0 0 0 1 1 0 1 5 4 49
17 0 0 0 0 2 3 1 1 6 11 52
18 1 1 0 0 2 2 1 1 5 10 45
19 1 0 0 0 1 2 1 0 5 3 61
20 1 0 0 0 1 5 1 1 3 7 45
21 0 1 0 0 1 2 1 1 3 6 10
22 0 0 0 0 2 5 1 1 5 13 35
23 0 0 0 0 1 2 1 3 3 7 5
24 0 0 1 0 1 4 1 3 3 9 55
25 1 0 0 1 2 5 1 1 4 9 50
26 1 0 0 1 2 5 1 1 4 12 41
27 1 0 0 0 2 3 1 1 5 11 34
28 0 0 0 0 2 2 1 1 5 11 73
29 1 0 0 0 2 2 1 1 3 7 3
30 0 0 0 0 1 3 1 1 4 8 135
31 1 0 0 0 2 4 1 1 5 11 82
32 0 0 0 1 2 4 1 1 6 17 20
33 0 0 0 0 2 4 1 1 5 5 27
34 0 0 0 0 2 2 1 1 3 3 45
35 0 0 0 0 2 2 1 0 1 2 60
36 0 0 0 0 1 3 1 1 4 5 24
37 0 0 0 0 2 3 1 1 6 9 15
38 0 0 0 0 2 2 1 1 6 6 67
39 0 0 0 1 1 4 1 1 3 6 85
40 0 0 0 1 2 4 1 1 5 5 35
41 1 0 0 0 2 3 1 1 3 4 84
42 0 0 0 0 1 5 1 1 3 4 62
MASTER CHART
CaseNo Misc_Headache Misc_Abortion Misc_TB Misc_Epist Diag_MajorCr Diag._MinorCr ClinicalCr.Met ACRCr.Met TotalScore ITASScore ESR
43 1 0 0 0 2 2 1 1 5 4 35
44 0 0 0 0 2 2 1 0 2 5 3
45 1 0 0 0 2 3 1 1 3 14 24
46 1 0 0 0 2 1 1 1 4 3 5
47 0 0 0 0 1 6 1 1 3 8 13
48 0 1 0 0 2 2 1 1 3 3 28
49 0 0 0 0 2 2 1 1 6 7 23
50 0 1 0 0 2 2 1 1 5 9 60
51 1 0 0 0 2 2 1 1 4 7 65
52 0 0 0 0 2 3 1 1 4 11 51
53 0 0 0 0 2 0 1 1 6 5 13
54 0 0 0 0 2 5 1 1 5 12 13
55 1 1 1 0 2 4 1 1 3 6 35
56 1 0 0 0 2 6 1 1 5 9 17
57 0 0 0 0 1 4 1 0 2 5 120
58 0 0 0 0 1 2 1 0 2 10 5
59 1 0 0 0 2 3 1 1 6 11 80
60 0 0 0 0 2 3 1 1 4 11 77
61 1 0 0 0 2 4 1 1 5 11 15
62 1 0 1 0 2 4 1 0 2 10 40
63 0 1 0 0 2 3 1 1 3 14 108
64 1 0 0 0 2 3 1 1 6 18 30
65 0 1 0 0 2 2 1 1 4 7 80
66 0 1 0 0 2 4 1 1 5 6 43
67 1 0 0 0 2 5 1 1 4 10 20
68 0 0 0 0 2 4 1 1 3 9 20
69 0 1 0 0 1 3 1 1 3 5 51
70 0 0 0 0 2 5 1 1 6 8 30
71 1 0 0 0 2 3 1 1 3 5 30
72 1 0 0 0 2 6 1 1 6 5 52
73 1 0 0 0 2 3 1 1 4 10 32
74 1 0 0 0 2 3 1 1 6 13 40
75 0 0 0 0 2 3 1 1 5 11 26
76 1 0 0 0 2 3 1 1 5 15 30
77 1 0 0 0 2 6 1 1 6 9 52
78 0 0 0 0 2 3 1 1 5 5 30
79 0 0 0 0 2 4 1 1 6 7 30
80 1 0 0 0 2 2 1 1 4 8 21
81 1 0 0 0 1 1 0 0 2 3 14
82 1 1 0 0 2 4 1 1 5 1 30
83 0 0 1 0 2 2 1 1 3 3 5
84 0 0 0 0 2 2 1 1 5 6 27
MASTER CHART
CaseNo Misc_Headache Misc_Abortion Misc_TB Misc_Epist Diag_MajorCr Diag._MinorCr ClinicalCr.Met ACRCr.Met TotalScore ITASScore ESR
85 0 0 1 0 0 0 0 1 3 2 5
86 0 0 0 0 2 2 1 1 6 1 25
87 0 0 1 0 2 2 1 1 5 5 81
88 0 0 0 0 2 2 1 1 5 4 23
89 1 0 0 0 2 2 1 1 4 4 34
90 0 0 0 0 2 2 1 1 4 4 10
91 0 0 0 0 3 2 1 1 4 5 95
92 0 0 0 0 2 3 1 1 5 4 73
93 0 0 0 0 2 3 1 1 5 4 25
94 1 0 0 0 1 2 1 1 4 12 5
95 1 0 1 1 2 3 1 1 4 5 96
96 0 0 1 0 1 2 1 1 3 3 31
97 1 1 0 0 2 2 1 1 5 3 42
98 1 1 0 0 1 3 1 1 4 3 84
99 1 0 0 0 2 3 1 1 4 13 8
100 1 0 0 0 1 3 1 1 3 5 46
101 0 0 0 0 2 4 1 1 4 5 20
102 0 0 0 0 1 0 0 0 2 3 25
103 0 0 0 0 2 2 1 1 4 9 70
104 1 0 0 0 2 3 1 1 5 7 26
105 1 0 0 0 1 3 1 0 1 4 47
106 0 0 0 0 1 1 0 0 2 6 31
107 0 0 0 0 2 2 1 1 4 9 39
108 1 0 0 0 1 2 1 0 2 2 2
109 0 0 0 0 2 2 1 1 4 4 2
110 0 0 0 0 2 2 1 1 3 3 73
111 0 0 0 0 2 1 1 1 4 4 6
112 1 0 0 0 2 1 1 1 4 3 15
113 1 0 0 0 1 2 1 0 2 2 60
114 1 0 0 0 2 2 1 1 4 4 32
115 1 0 0 0 2 1 1 1 5 4 38
116 0 0 0 0 2 3 1 1 3 4 35
117 0 0 0 0 2 2 1 1 4 3 10
118 1 0 0 0 1 3 1 1 5 11 61
119 0 0 0 0 1 3 1 1 3 6 98
120 1 0 0 0 2 3 1 1 3 5 74
121 1 0 0 0 2 2 1 1 5 6 90
122 0 0 0 0 2 3 1 1 5 7 43
123 0 0 0 0 2 1 1 1 4 6 20
124 0 0 0 0 2 1 1 1 4 5 54
125 1 0 0 0 2 2 1 0 2 3 35
MASTER CHART
CaseNo ESR_CRP cIMTRt cIMTRt Avg. cIMTLt cIMTLt avg. Aorta_Asc Aorta_Arch Aorta_Desc Aorta_Abd Innominate lesion CaseNo
1 1.00  0 1 1 0 1 1
2 0.00 .53/.54/.57 0.55 .43/.50/.63 0.52 1 0 1 0 0 2
3 0.00  0 0 0 0 0 3
4 0.00  0 0 0 0 0 4
5 1.00  0 0 0 0 0 5
6 0.00  0 0 1 0 1 6
7 1.00  0 0 0 0 1 7
8 0.00 .51/52/.52 0.52 .58/.56/.56 0.57 0 1 0 0 0 8
9 1.00  0 0 0 0 0 9
10 0.00  1 0 0 0 0 10
11 1.00 1.33/1.26/1.20 1.26 1.26/1.34/1.47 1.36 0 0 1 0 0 11
12 0.00 .53/.63/.50 0.55 .47/.43/.57 0.49 0 0 0 0 0 12
13 0.00  0 0 0 0 0 13
14 1.00  1 0 0 1 0 14
15 0.00  0 0 0 0 0 15
16 1.00  0 0 0 0 1 16
17 0.00  0 0 1 1 0 17
18 1.00  0 0 0 0 0 18
19 0.00 .56/.57/.67 0.60 .47/.67/.57 0.57 0 0 0 0 0 19
20 1.00 .53/.60/.52 0.55 .6/.54/.57 0.57 0 0 1 1 0 20
21 0.00  0 0 0 1 0 21
22 1.00  0 0 1 1 0 22
23 0.00 .47/.65/.54 0.55 .6/.54/.52 0.55 0 0 0 1 0 23
24 0.00  1 0 0 0 0 24
25 0.00  0 1 1 0 1 25
26 1.00  1 0 0 0 0 26
27 0.00  0 0 0 0 0 27
28 0.00 .63/.52/.60 0.58 .47/.50/.60 0.52 0 0 0 1 0 28
29 0.00 .7/.77/.74 0.74 .49/.63/.51 0.54 0 0 0 1 0 29
30 0.00 .72/.61/.60 0.64 .56/.50/.60 0.55 0 0 1 0 0 30
31 1.00  0 0 0 0 0 31
32 0.00  0 0 0 0 0 32
33 0.00  0 0 0 1 0 33
34 1.00  0 1 0 0 0 34
35 1.00  0 0 0 0 0 35
36 0.00 .78/.67/.60 0.68 .54/.67/.56 0.59 0 0 0 1 0 36
37 0.00 .86/1.02/.90 0.93 .90/.73/.80 0.81 1 0 0 1 0 37
38 0.00  0 0 0 0 0 38
39 1.00 .98/.87/.80 0.88 .87/.94/1.03 0.95 0 0 1 0 0 39
40 1.00 .96/1.0/.96 0.97 1.41/1.27/1.26 1.31 0 0 0 1 0 40
41 1.00  1 0 0 0 0 41
42 1.00 .77/.70/.73 0.73 .66/.81/.87 0.78 1 0 1 1 0 42
MASTER CHART
CaseNo ESR_CRP cIMTRt cIMTRt Avg. cIMTLt cIMTLt avg. Aorta_Asc Aorta_Arch Aorta_Desc Aorta_Abd Innominate lesion CaseNo
43 0.00 .43/.50//.60 0.51 .51/.52/.57 0.53 0 0 0 0 0 43
44 0.00  0 0 0 0 0 44
45 1.00 .37/.38/.37 0.37 .90/.93/1.13 0.99 0 0 1 0 0 45
46 0.00 .66/.47/.50 0.54 .60/.63/.57 0.60 0 0 0 0 0 46
47 0.00  0 0 1 0 0 47
48 0.00 .46/.74/.57 0.59 .76/.70/.63 0.70 0 0 0 0 0 48
49 1.00 .87/.90/.83 0.87 1.1./1.03/1.06 1.06 1 0 0 0 0 49
50 1.00 .73/.68/.72 0.71 .60/.64/.68 0.64 0 0 0 0 0 50
51 0.00 1.23/.97/1.08 1.09 .93/1.08/.90 0.97 0 0 0 0 0 51
52 0.00  1 0 0 0 0 52
53 0.00 .67/.67/.86 0.73 1.0/1.02/.93 0.98 0 0 0 0 0 53
54 0.00  1 0 1 0 1 54
55 0.00 .50/.47/.44 0.47 .44/.48/.39 0.44 0 0 1 1 0 55
56 0.00  0 0 1 1 0 56
57 1.00 1.34/1.28/1.24 1.29 1.16/1.18/1.18 1.17 0 0 1 1 0 57
58 0.00 ,54/.56/.56 0.55 .52/.52/.54 0.53 0 0 0 1 0 58
59 1.00  0 0 0 0 1 59
60 1.00  0 0 0 0 0 60
61 0.00  0 0 0 0 0 61
62 0.00 .88/.90/.88 0.89 .94/.92/.92 0.93 1 0 0 1 0 62
63 1.00 .68/.70/.72 0.70 1.04/1.06/1.04 1.05 0 0 0 1 0 63
64 0.00  0 0 0 1 0 64
65 1.00 1.04/1.06/1.06 1.05 1.08/1.08/1.06 1.07 0 0 0 1 0 65
66 1.00  0 0 0 1 0 66
67 1.00  1 0 0 1 0 67
68 0.00  0 0 1 1 0 68
69 1.00 1.02/1.0/1.02 1.01 .98/1.0/1.0 0.99 0 0 0 1 0 69
70 0.00  1 0 1 0 0 70
71 1.00  0 0 1 1 1 71
72 1.00  1 0 0 1 1 72
73 0.00  0 0 1 0 0 73
74 0.00 .50/.52/.52 0.51 .56/.60/.64 0.60 0 0 0 0 0 74
75 1.00  0 0 0 0 0 75
76 1.00  0 0 0 0 0 76
77 1.00  0 0 0 0 0 77
78 0.00  0 0 0 0 0 78
79 0.00  1 0 0 0 0 79
80 1.00  0 0 0 0 0 80
81 0.00 .68/.66/.58 0.64 .80/.84/.88 0.84 0 0 0 0 0 81
82 0.00 .88/.86/.88 0.87 .96/.98/.96 0.97 0 0 0 0 0 82
83 0.00 .56/.54/.54 0.55 .56/.60/.62 0.59 0 0 0 0 0 83
84 1.00 .96/.98/.98 0.97 1.02/1.04/1.04 1.03 0 0 0 0 0 84
MASTER CHART
CaseNo ESR_CRP cIMTRt cIMTRt Avg. cIMTLt cIMTLt avg. Aorta_Asc Aorta_Arch Aorta_Desc Aorta_Abd Innominate lesion CaseNo
85 0.00  0 0 0 0 0 85
86 1.00 .5/.5/.5 0.50 .53/.54/.63 0.57 1 0 0 0 0 86
87 0.00  0 0 0 1 0 87
88 1.00 .68/.66/.64 0.66 .66/.68/.68 0.67 0 0 0 0 0 88
89 1.00  0 0 0 1 0 89
90 0.00  0 0 0 0 0 90
91 1.00 1.26/1.24/1.24 1.25 1.16/1.18/1.18 1.17 0 0 0 0 0 91
92 1.00  0 0 1 0 0 92
93 0.00  0 0 1 1 0 93
94 0.00  0 0 0 0 0 94
95 1.00  0 0 0 0 1 95
96 0.00  0 0 0 0 0 96
97 1.00  0 0 0 0 0 97
98 1.00 .60/.62/.64 0.62 .54/.60/.64 0.59 0 0 0 1 0 98
99 0.00  0 0 0 0 0 99
100 0.00  0 0 0 0 1 100
101 0.00 .62/.64/.66 0.64 .60/.62/.62 0.61 0 0 0 1 0 101
102 0.00 .68/.66/.68 0.67 .58/.56/.56 0.57 0 0 0 0 0 102
103 1.00 1.28/1.24/1.24 1.25 1.18/1.16/1.16 1.17 1 0 0 0 0 103
104 1.00  0 0 0 1 1 104
105 0.00  0 0 1 0 0 105
106 0.00 .60/.64/.58 0.61 .50/.54/.54 0.53 0 0 0 1 0 106
107 0.00 .64/.66/.60 0.63 .48/.50/.52 0.50 0 0 0 0 0 107
108 0.00  0 0 0 1 0 108
109 0.00  0 0 0 0 0 109
110 1.00  0 0 1 0 0 110
111 0.00 .56/.56/.58 0.57 .54/.50/.50 0.51 0 0 0 0 0 111
112 0.00 .96/.98/.98 0.97 .90/.88/.88 0.89 0 0 0 0 0 112
113 1.00  0 0 0 0 0 113
114 0.00  0 0 0 0 1 114
115 1.00  0 0 0 0 1 115
116 0.00 .62/.60/.64 0.62 .56/.54/.54 0.55 0 0 0 1 0 116
117 0.00  0 0 0 0 0 117
118 0.00  0 0 0 0 0 118
119 1.00  0 0 1 1 0 119
120 0.00  0 0 1 0 0 120
121 1.00 1.28/1.26/1.26 1.27 1.02/1.06/1.08 1.05 0 0 0 0 0 121
122 1.00  0 0 1 1 0 122
123 0.00  0 0 0 0 1 123
124 0.00 .86/.88/.90 0.88 .80/.82/.84 0.82 0 0 0 0 0 124
125 1.00 .68/.64/.68 0.67 .60/.62/.64 0.62 0 0 0 0 0 125
MASTER CHART
LSCA Lesion RVA lesion LVA lesion RCCA lesion LCCA lesion RICA liones LICA lesion CorArt lesion PulmArt lesion CeliacArt lesion CaseNo
1 0 0 1 1 0 0 1 0 0 1
1 0 1 0 0 0 0 0 0 2
1 0 0 0 1 0 0 1 0 1 3
1 0 1 0 1 0 0 0 0 0 4
1 0 1 1 1 0 0 0 0 0 5
1 1 1 1 1 0 0 0 0 1 6
1 0 1 0 1 0 0 0 0 0 7
1 0 0 0 0 0 0 0 0 0 8
1 0 0 1 1 0 0 0 0 1 9
1 0 0 0 1 0 0 0 0 1 10
1 0 1 0 0 0 0 0 0 1 11
0 0 0 0 0 0 0 0 0 0 12
1 0 1 1 1 0 0 0 1 0 13
1 0 1 1 1 0 0 0 0 1 14
1 0 1 0 0 0 0 0 0 1 15
0 0 0 0 0 0 0 0 0 1 16
1 1 1 1 0 0 0 0 0 0 17
1 0 0 1 1 0 0 0 18
0 0 0 0 0 0 0 1 19
0 0 0 0 0 0 0 0 20
0 0 0 0 0 0 0 0 0 0 21
1 0 0 0 1 0 0 0 0 1 22
0 0 0 0 0 0 0 0 0 0 23
0 0 0 0 1 0 0 0 0 0 24
1 0 0 1 0 0 0 1 0 0 25
1 0 1 0 1 0 0 1 0 0 26
1 0 0 0 1 0 0 0 1 1 27
1 0 0 0 0 0 0 0 0 28
0 0 0 0 0 0 0 0 0 0 29
0 0 0 0 0 0 0 0 0 30
0 1 0 1 0 0 0 0 31
1 0 0 0 1 0 0 1 0 0 32
0 0 0 0 1 0 0 0 0 1 33
1 0 0 0 1 0 0 0 0 34
1 0 0 0 1 0 0 1 1 35
0 0 0 0 0 0 0 0 0 1 36
1 0 0 0 0 0 0 1 37
1 0 0 0 1 0 0 0 0 1 38
0 0 0 0 0 0 0 1 1 39
1 0 0 0 0 0 0 0 0 1 40
1 0 0 1 1 0 0 1 0 0 41
0 0 0 0 0 0 0 0 0 0 42
MASTER CHART
LSCA Lesion RVA lesion LVA lesion RCCA lesion LCCA lesion RICA liones LICA lesion CorArt lesion PulmArt lesion CeliacArt lesion CaseNo
0 0 0 0 0 0 0 1 0 1 43
0 0 0 1 1 0 0 0 0 0 44
0 0 0 0 0 0 0 0 1 1 45
1 0 0 0 0 0 0 0 0 1 46
0 0 0 1 1 0 0 1 1 1 47
0 0 0 0 0 0 0 0 0 1 48
1 0 0 0 0 0 0 1 49
0 1 0 0 0 0 0 0 0 1 50
0 0 0 0 0 0 0 1 51
1 0 0 0 0 0 1 1 1 52
0 0 0 0 0 0 0 0 0 0 53
1 0 0 1 1 0 0 0 0 0 54
0 0 0 0 0 0 0 1 55
1 0 0 0 1 0 0 1 1 56
0 0 0 0 0 0 0 0 0 57
0 0 0 0 0 0 0 0 0 1 58
1 0 0 1 1 0 0 0 0 0 59
1 0 0 1 1 1 1 0 0 0 60
1 1 0 1 1 0 0 0 1 61
0 0 0 0 0 0 0 0 0 1 62
0 0 0 0 0 0 0 0 0 0 63
1 0 0 0 0 0 1 0 0 1 64
0 0 0 0 0 0 0 0 0 0 65
1 0 0 0 1 0 0 0 0 1 66
0 0 0 0 1 0 0 0 0 1 67
0 0 0 0 0 0 0 0 0 0 68
0 0 0 0 0 0 0 0 0 0 69
1 0 0 0 1 0 0 0 0 0 70
1 0 0 1 1 0 0 0 0 0 71
1 0 0 0 1 0 0 0 0 1 72
1 0 0 0 1 0 0 0 0 0 73
0 0 0 1 0 0 0 0 0 1 74
0 0 0 0 1 0 0 0 0 75
1 0 0 1 1 0 0 0 0 1 76
1 0 0 0 1 0 0 0 0 1 77
1 0 0 1 1 0 0 0 0 0 78
1 0 0 0 1 0 0 0 0 0 79
1 0 0 1 1 0 0 0 0 1 80
0 0 0 0 0 0 0 0 0 0 81
1 0 0 0 0 0 0 0 0 1 82
0 0 0 0 0 0 0 0 0 1 83
0 1 0 0 0 0 0 0 0 0 84
MASTER CHART
LSCA Lesion RVA lesion LVA lesion RCCA lesion LCCA lesion RICA liones LICA lesion CorArt lesion PulmArt lesion CeliacArt lesion CaseNo
0 0 0 0 0 0 0 0 0 1 85
1 0 0 0 0 0 0 0 0 0 86
0 0 0 0 0 0 0 0 0 0 87
1 0 0 0 0 0 0 0 0 0 88
1 0 0 0 0 1 0 0 0 1 89
1 0 0 1 0 0 0 0 0 0 90
1 0 0 1 0 0 0 1 1 0 91
1 0 0 0 1 0 0 0 1 0 92
1 0 0 0 0 0 0 1 93
0 0 0 1 1 0 0 1 94
1 0 0 1 1 0 0 0 0 0 95
0 0 0 0 0 0 0 0 0 96
1 0 0 0 0 0 0 0 0 97
1 0 0 0 0 0 0 0 0 0 98
1 1 1 1 1 0 0 0 1 0 99
0 0 1 0 1 0 0 1 0 1 100
1 0 0 0 0 0 0 0 0 0 101
0 0 0 0 0 0 0 0 0 1 102
1 0 0 0 0 0 0 0 0 0 103
1 0 0 1 1 1 0 0 0 1 104
1 0 0 0 0 0 0 0 0 0 105
0 0 0 0 0 0 0 0 0 0 106
1 0 0 0 0 0 0 0 0 0 107
0 0 0 0 1 0 0 0 0 0 108
1 0 0 1 0 0 0 1 0 1 109
1 0 0 1 1 0 0 0 0 1 110
1 0 0 0 0 0 0 1 0 0 111
0 0 0 0 0 0 0 0 0 0 112
0 0 0 0 0 0 0 0 0 0 113
1 0 1 0 1 0 0 0 0 0 114
0 0 0 1 0 0 0 0 0 0 115
0 0 0 0 0 0 0 0 0 0 116
1 0 0 0 0 0 0 0 0 0 117
1 1 1 1 1 0 0 1 0 1 118
0 0 0 0 0 0 0 0 0 0 119
1 0 0 0 0 0 0 0 0 1 120
1 0 0 0 0 0 0 0 0 0 121
1 0 0 0 1 0 0 0 0 0 122
0 1 0 1 1 0 0 0 0 0 123
1 0 0 0 0 0 0 0 0 124
1 0 0 0 0 0 0 0 0 1 125
MASTER CHART
SMA lesion IMA lesion RRA lesion LRA lesion bilate RA lesion Iliac lesion CFA lesion SFA lesion ClinicalCr C+ ClinicalCr P+ CaseNo
0 0 0 1 0.00 0 0 0 1 0 1
0 0 0 0 0.00 0 0 0 0 2
1 0 1 0 0.00 0 0 0 1 0 3
0 0 0 0 0.00 0 0 0 0 0 4
0 0 0 0 0.00 0 0 0 0 0 5
0 0 0 1 0.00 0 0 0 0 0 6
1 0 0 0 0.00 0 0 0 0 0 7
0 0 0 0 0.00 1 1 0 0 0 8
0 0 0 0 0.00 0 0 0 0 0 9
1 0 0 0 1.00 0 0 0 0 0 10
0 0 0 0 0.00 0 0 0 0 0 11
0 0 0 0 1.00 0 0 0 0 0 12
1 0 0 0 0.00 0 0 0 0 1 13
1 0 0 0 0.00 0 0 0 0 0 14
0 0 0 0 0.00 0 0 0 0 0 15
1 0 0 0 0.00 0 0 0 0 0 16
0 0 0 0 1.00 1 0 0 0 0 17
0 0 0 0 0.00 0 0 0 0 0 18
0 0 0 0 1.00 0 0 0 19
1 0 0 1 0.00 0 0 0 20
0 0 0 0 1.00 1 0 0 0 0 21
1 0 0 1 0.00 1 0 0 0 0 22
0 0 1 0 0.00 1 0 0 0 0 23
0 0 0 0 0.00 0 0 0 0 0 24
0 0 0 0 0.00 0 0 1 1 0 25
0 0 0 0 0.00 0 0 0 1 0 26
0 0 0 0 0.00 0 0 0 0 1 27
0 0 0 0 0.00 0 0 0 0 28
0 0 1 0 0.00 0 0 0 0 0 29
0 0 0 0 0.00 0 0 0 0 30
0 0 0 0 1.00 0 0 0 31
0 0 0 0 0.00 0 0 0 1 0 32
0 0 0 0 0.00 0 0 0 0 0 33
0 0 0 0 0.00 0 0 0 0 34
1 0 0 0 1.00 0 0 0 1 35
1 0 0 0 1.00 0 0 0 0 0 36
1 1 0 1 0.00 0 0 0 37
0 0 0 0 0.00 0 0 0 0 0 38
0 0 0 0 0.00 0 0 0 1 39
0 0 1 0 0.00 1 0 0 0 0 40
0 0 0 0 0.00 0 0 0 1 0 41
0 0 0 0 0.00 0 0 0 0 0 42
MASTER CHART
SMA lesion IMA lesion RRA lesion LRA lesion bilate RA lesion Iliac lesion CFA lesion SFA lesion ClinicalCr C+ ClinicalCr P+ CaseNo
1 0 0 1 0.00 0 0 0 1 0 43
0 0 0 0 0.00 0 0 0 0 0 44
1 0 0 1 0.00 0 0 0 0 1 45
0 0 0 0 0.00 0 0 0 0 0 46
1 0 0 0 0.00 0 0 0 1 1 47
1 1 0 0 1.00 0 0 0 0 0 48
0 0 0 0 0.00 0 0 0 49
0 0 0 0 0.00 0 0 0 0 0 50
0 0 1 0 0.00 0 0 0 51
1 0 1 0 0.00 0 0 1 1 0 52
1 0 0 0 0.00 0 0 0 0 0 53
1 0 0 0 0.00 0 0 0 0 0 54
0 0 0 1 0.00 0 0 0 55
1 0 0 0 1.00 0 0 0 1 56
0 0 1 0 0.00 0 0 0 0 57
1 0 0 0 1.00 0 0 0 0 0 58
1 0 0 0 0.00 0 0 0 0 0 59
0 0 0 0 0.00 0 0 0 0 0 60
1 0 0 0 0.00 0 0 0 0 61
0 0 1 0 0.00 0 0 0 0 0 62
1 0 0 1 0.00 0 0 0 0 0 63
1 0 0 0 1.00 1 0 0 0 0 64
0 0 1 0 0.00 0 0 0 0 0 65
1 0 0 0 1.00 0 0 0 0 0 66
1 0 0 0 1.00 0 0 0 0 0 67
0 0 0 1 0.00 0 0 0 0 0 68
0 0 1 0 0.00 0 0 0 0 0 69
0 0 0 0 1.00 0 0 0 0 0 70
0 0 0 0 0.00 0 0 0 0 0 71
0 0 1 0 0.00 0 0 0 0 0 72
0 0 0 0 0.00 0 0 0 0 0 73
0 0 0 1 0.00 0 0 0 0 0 74
0 0 0 0 0.00 0 0 0 0 75
0 0 0 0 0.00 0 0 0 0 0 76
0 0 1 0 0.00 0 0 0 0 0 77
1 0 0 0 0.00 0 0 0 0 0 78
0 0 0 0 1.00 0 0 0 0 0 79
0 0 0 0 0.00 0 0 0 0 0 80
0 0 0 1 0.00 0 0 0 0 0 81
1 0 0 0 1.00 0 0 0 0 0 82
0 0 0 0 0.00 0 0 0 0 0 83
0 0 0 0 0.00 0 0 0 0 0 84
MASTER CHART
SMA lesion IMA lesion RRA lesion LRA lesion bilate RA lesion Iliac lesion CFA lesion SFA lesion ClinicalCr C+ ClinicalCr P+ CaseNo
0 0 0 0 0.00 0 0 0 0 0 85
0 0 0 0 0.00 0 0 0 0 0 86
0 0 0 1 0.00 1 0 0 0 0 87
0 0 0 0 0.00 0 0 0 0 0 88
0 0 0 0 0.00 1 0 0 0 0 89
0 0 0 0 0.00 0 0 0 0 0 90
0 0 0 0 0.00 0 0 0 1 1 91
0 0 0 0 0.00 0 0 0 0 1 92
0 0 0 0 0.00 0 0 0 93
0 0 0 0 0.00 0 0 0 94
1 0 0 0 1.00 0 0 0 0 0 95
0 0 0 0 1.00 0 0 0 0 96
0 0 0 0 0.00 0 0 0 0 97
0 0 0 0 0.00 0 0 0 0 0 98
0 0 0 1 0.00 0 0 0 0 1 99
0 0 1 0 0.00 0 0 0 1 0 100
0 0 0 0 1.00 0 0 0 0 1 101
1 0 0 0 1.00 0 0 0 0 1 102
0 0 0 0 0.00 0 0 0 0 0 103
1 0 0 1 0.00 0 0 0 0 0 104
0 0 0 0 0.00 0 0 0 0 0 105
0 0 0 0 1.00 0 0 0 0 0 106
0 0 0 0 0.00 0 0 0 0 0 107
0 0 0 0 0.00 1 0 0 0 0 108
1 0 0 1 0.00 0 0 0 1 0 109
1 0 0 0 0.00 0 0 0 0 0 110
0 0 0 1 0.00 0 0 0 1 0 111
0 0 0 1 0.00 0 0 0 0 0 112
0 0 0 1 0.00 0 0 0 0 0 113
0 0 0 0 0.00 0 0 0 0 0 114
0 0 0 0 0.00 0 0 0 0 0 115
0 0 0 0 1.00 0 0 0 0 0 116
0 0 0 0 0.00 0 0 0 0 0 117
0 0 1 0 0.00 0 0 0 1 0 118
0 0 0 0 1.00 0 0 0 0 0 119
1 0 0 0 1.00 0 0 0 0 0 120
0 0 0 0 0.00 0 0 0 0 0 121
0 0 1 0 0.00 0 0 0 0 0 122
0 0 0 0 0.00 0 0 0 0 0 123
0 0 0 0 0.00 0 0 0 0 0 124
1 0 0 0 1.00 0 0 0 0 0 125
MASTER CHART
Ds Activity on first visit Ds activity on last follow up visit Type of T.A. Resp.of Med.Tt Response of Intervent. Tt.
1 3 2 1 1
3 1 3 3 4
3 3 5 1 2
2 2 1 3 1
1 2 1 2 1
2 2 5 2 1
1 1 1 3 1
3 3 5 2 1
1 1 5 3 1
2 2 5 2 2
1 1 2 3 2
2 2 3 2 1
2 3 5 1 1
1 1 5 4 4
2 2 1 2 1
1 3 5 1 1
2 3 5 1 2
1 1 1 4 4
2 2 3 2 1
1 2 4 2 1
3 2 4 3 1
1 1 5 4 4
3 3 4 4 4
2 3 1 1 4
2 2 5 2 2
1 1 1 3 1
2 2 5 2 2
2 2 5 2
3 3 4 1 1
2 2 2 2 4
1 2 5 2 2
2 1 2 2
2 3 5 1 1
1 2 1 2 1
1 2 5 2 2
2 5 1 1
3 3 5 1 4
1 2 5 2 3
1 2 2 2 1
1 1 5 3 2
1 3 1 1 2
1 5 4
MASTER CHART
Ds Activity on first visit Ds activity on last follow up visit Type of T.A. Resp.of Med.Tt Response of Intervent. Tt.
2 1 5 3 1
3 3 1 1 1
1 2 4 2 2
3 3 5 1 1
2 2 5 2 1
1 3 5 1 1
1 1 1 3 4
1 2 1 2 2
2 1 3 3 4
2 2 5 2 4
3 3 1 1 4
3 3 5 1 2
2 3 3 1 4
2 2 5 2 1
1 1 3 1 1
3 3 4 1 1
1 1 1 3 2
1 1 1 3 2
2 2 5 2 2
2 4 1 4
1 3 5 1 2
2 3 5 1 1
1 2 5 3 2
1 1 5 3 2
1 3 5 1 2
2 3 2 1 1
1 1 3 3 2
2 2 5 2 2
1 1 3 3 1
1 3 5 1 2
2 2 2 2 2
2 3 5 1 1
1 1 1 4
1 1 1 3 1
1 3 5 1 2
2 2 1 2 1
2 2 5 2 1
1 2 3 2 4
2 3 4 1 4
2 3 3 1 2
3 2 4 2 4
1 3 1 1 1
MASTER CHART
Ds Activity on first visit Ds activity on last follow up visit Type of T.A. Resp.of Med.Tt Response of Intervent. Tt.
3 2 3 2
1 2 1 2 4
2 2 3 3 4
1 2 1 2 3
1 2 5 2 2
2 1 1 3 1
1 1 1 3 1
1 1 5 3 4
2 2 5 2
3 3 1 2 4
1 3 5 1 2
2 2 2 2 2
1 1 1 3
1 1 4 3 4
2 2 5 2 4
2 2 5 2 4
2 3 5 1 3
2 3 2 1 1
1 3 1 4 4
1 2 5 2 1
2 2 2 2 1
2 2 3 2 4
2 2 1 2 4
3 3 5 2 1
2 2 5 2 4
1 2 3 2 2
3 3 1 2 4
3 3 5 1 1
1 3 3 1 4
2 2 1 4 4
1 1 1 4 4
2 1 5 3 1
3 3 1 2 2
2 2 5 3 4
1 1 4 4 4
2 2 5 4 4
1 1 1 3 2
1 1 5 3 1
2 3 1 1 1
2 2 1 2 4
1 2 3 2 1
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Takayasu Arteritis Demographic Features, Diagnosis, Clinical Presentation and Angiographic Profile.
1 Abstract AIM: To study the demographic profile, clinical presentation, diagnostic features,
angiographic findings and treatment outcomes of patients with Takayasu arteritis. SPECIFIC
OBJECTIVES : 1. To study the demographic profile of Indian patients with Takayasu arteritis. 2. To
study the modes of clinical presentation of patients with Takayasu arteritis. 3. Evaluation of the
applicability of different diagnostic criteria to Indian patients with Takayasu arteritis. 4. To study the
angiographic findings in Takayasu arteritis based on aortography, peripheral and coronary
angiography and to...
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